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Abstract           
  
Osteoarthritis (OA) is a whole-joint disease characterized by articular cartilage 
degeneration, tissue inflammation, abnormal bone formation and extracellular matrix 
(ECM) mineralization. This disease leads to severely impaired life quality of patients. 
Currently, there is still no cure or approved therapies capable of modifying the OA course. 
Treatment is limited to the use of therapeutic strategies with modest efficacy that, in some 
cases, cause undesirable side effects. The identification of new and effective disease 
modifying drugs, without side-effects, is important for the OA treatment. Natural products 
are potential sources of therapeutics agents for the OA treatment. Recent data indicating 
the anti-inflammatory activity of meroditerpenoids isolated from the brown algae 
Cystoseira usneoides suggest its potential as therapeutics of the inflammatory-related 
diseases. In this thesis, in order to explore the potential of three of these meroditerpenoids 
as novel therapeutic agents for OA, we evaluated its anti-inflammatory potential using in 
vitro inflammation models. We showed the anti-inflammatory activity of the 
meroditerpenoids amentadione (YP), cystodione G (Cyd G) and 11-hydroxyamentadione 
(Cyd K) in inflammatory conditions induced by calcium crystals. We also showed the anti-
inflammatory activity of the meroditerpenoid YP in a IL-1β-stimulated human articular 
primary cells system. To further study the OA condition and to test and validate new drugs 
for OA, we started to develop a three-dimensional (3D) in vitro/ex vivo OA-model that 
recreates the human articular system and the OA conditions. Our preliminary studies have 
demonstrated that healthy articular cartilage explants are able to recreate in vitro/ex vivo 
the inflammatory and mineralizing OA conditions. We have also shown that these tissue 
cartilage explants are able to recreate the inflammatory OA conditions in a co-culture with 
primary synoviocyes. In conclusion, our results suggest the therapeutic potential of the 
meroditerpenoid YP in OA disease, and provide initial steps towards the development of 
an 3D OA-model. 
 
Keywords: Osteoarthritis, inflammation, ectopic calcification, in vitro osteoarthritis 
models. 
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Resumo 
 
A osteoartrite (OA) é uma doença que afeta toda a articulação, sendo caracterizada 
por degeneração da cartilagem articular, inflamação tecidular, formação óssea anormal e 
mineralização da matriz extracelular. Esta doença leva a perda significativa da qualidade 
de vida dos doentes. Atualmente, ainda não existe cura ou terapias aprovadas capazes de 
modificar o curso da OA. O tratamento é limitado ao uso de estratégias terapêuticas com 
eficácia modesta e que, em alguns casos, causam efeitos secundários indesejáveis. A 
identificação de novos e eficazes fármacos modificadores da doença, sem efeitos 
secundários, é importante para o tratamento da OA. Os produtos naturais são potenciais 
fontes de agentes terapêuticos para o tratamento da OA. Dados recentes indicando a 
atividade anti-inflamatória de meroditerpenóides isolados da alga castanha Cystoseira 
usneoides sugerem o seu potencial como terapêutica de doenças inflamatórias. Nesta tese, 
para explorar o potencial de três desses meroditerpenóides como novos agentes 
terapêuticos para a OA, foi avaliado o seu potencial anti-inflamatório, utilizando modelos 
de inflamação in vitro. Foi demonstrada a atividade anti-inflamatória dos 
meroditerpenóides amentadiona (YP), cistodiona G (Cyd G) e 11-hidroxiamentadiona 
(Cyd K) em condições inflamatórias induzidas por cristais de cálcio. Também foi mostrada 
a atividade anti-inflamatória do meroditerpenóide YP num sistema de células primárias 
articulares humanas estimuladas com IL-1β. Para futuramente estudar a OA e testar e 
validar novos fármacos para esta doença, começámos a desenvolver um modelo 
tridimensional (3D) de OA in vitro/ex vivo, que recria o sistema articular humano e as 
condições observadas na doença. Os estudos preliminares demonstraram que explantes de 
cartilagem articular saudável são capazes de recriar in vitro/ex vivo as condições 
inflamatórias e mineralizantes observadas na OA. Foi mostrado também que estes 
explantes de tecido cartilagíneo são capazes de recriar as condições inflamatórias de OA 
numa co-cultura com sinoviócitos primários. Em conclusão, os nossos resultados sugerem 
o potencial terapêutico do meroditerpenóide YP na OA, e fornecem passos iniciais para o 
desenvolvimento de um modelo 3D de OA. 
Palavras-chave: Osteoartrite, inflamação, calcificação ectópica, modelos de osteoartrite 
in vitro. 
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Resumo Alargado 
 
A osteoartrite (OA) é uma doença articular degenerativa crónica e progressiva. 
Representa a forma mais comum de artrite e uma das doenças crónicas mais frequentes em 
todo o mundo, afetando um elevado número de pessoas, essencialmente idosos. É uma 
doença multifatorial que geralmente resulta de fatores modificáveis e não modificáveis 
sistémicos e locais. A OA afeta as articulações sinoviais e caracteriza-se por alterações 
patológicas nos vários tecidos que as compõem, embora os principais tecidos afetados 
sejam a cartilagem articular, a membrana sinovial e o osso subcondral.   
 Nesta doença a cartilagem articular sofre significativas alterações na sua 
composição, estrutura e função, que culminam na degeneração do tecido. A interleucina 1β 
(IL-1β) e o fator de necrose tumural α (TNF-α) são as duas principais citocinas pró-
inflamatórias envolvidas no início e na progressão da OA. No início da doença, estas 
citocinas pró-inflamatórias começam a ser secretadas pelos condrócitos e promovem a 
supressão da síntese de colagénio e proteoglicanos necessários para manter a matriz 
extracelular (ECM), bem como a síntese de enzimas de degradação da ECM, 
essencialmente colagenases (metaloproteinases de matriz (MMPs)) e agrecanases 
(desintegrinas e metaloproteinases com motivos de trombospondina (ADAMTS)) que 
iniciam a degradação da ECM. Numa tentativa de manter a homeostase do tecido, os 
condrócitos tornam-se mais ativos, aumentam a proliferação celular, criam aglomerados de 
condrócitos e aumentam a atividade metabólica, aumentando a síntese dos componentes da 
ECM mas não suficiente para repor o equilíbrio. Desta forma, um desequilíbrio é gerado 
entre a síntese e a degradação da ECM da cartilagem articular, o que leva à sua progressiva 
degradação. A inflamação e a alteração da biomecânica articular promovem alterações 
fenotípicas nos condrócitos, que passam a expressar um fenótipo de células diferenciadas 
(hipertrofia e apoptose). Condrócitos hipertróficos contribuem para a degradação da ECM 
da cartilagem articular e também para a sua calcificação, uma característica 
consistentemente associada ao agravamento da doença. A calcificação da ECM ocorre 
através da deposição de cristais contendo cálcio, essencialmente cristais básicos de fosfato 
de cálcio (BCP). Estes cristais também contribuem para o processo de degradação da ECM 
da cartilagem articular, uma vez que induzem os condrócitos a produzir citocinas pró-
inflamatórias, MMPs e óxido nitríco (NO).       
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 A membrana sinovial é outro tecido significativamente afetado pela OA. A 
inflamação sinovial (sinovite) é uma característica comum associada à doença. Os eventos 
iniciais de degradação da ECM da cartilagem articular podem desempenhar um papel 
importante no desenvolvimento da inflamação da articulação osteoartrítica e 
especificamente da membrana sinovial. Uma vez iniciado o processo de degradação da 
ECM da cartilagem articular, os produtos de degradação são libertados no fluído sinovial 
(SF) e a membrana sinovial sofre alterações, tornando-se hipertrófica e hiperplásica. À 
medida que a doença progride, estas alterações histológicas são muitas vezes 
acompanhadas por neoangiogénese, fibrose e infiltração de células imunitárias, como 
macrófagos e linfócitos. Sinoviócitos e células imunitárias sintetizam e libertam no SF 
mediadores inflamatórios, como citocinas pro-inflamatórias e quimiocinas, que, para além 
de induzirem sinovite na membrana sinovial, também induzem a produção de mediadores 
catabólicos que, em conjunto com as citocinas pró-inflamatórias e as quimiocinas, 
contribuem para o fenótipo de condrócitos diferenciados e para a degradação da ECM da 
cartilagem articular. Os cristais básicos de fosfato de cálcio também estão presentes na 
membrana sinovial e no SF, e são capazes de induzir a proliferação dos sinoviócitos e a 
sinovite na membrana sinovial.         
 Como a cartilagem articular e a membrana sinovial, o osso subcondral também 
sofre alterações durante a progressão da OA. Em estágios iniciais da OA o osso subcondral 
apresenta alterações como o aumento da espessura da placa óssea subcondral e das 
trabéculas ósseas adjacentes. À medida que a doença progride, inicia-se um processo de 
remodelação óssea em áreas de destruição da cartilagem articular, que inclui o 
espessamento acentuado (esclerose) da placa óssea subcondral, e formação de cistos 
subcondrais e osteófitos. O osso subcondral também é uma fonte de mediadores 
inflamatórios, como citocinas pró-inflamatórias e enzimas de degradação da ECM, 
implicados no processo inflamatório na OA e na degradação da camada profunda da 
cartilagem articular. Em estágios avançados da doença, cristais básicos de fosfato de cálcio 
também podem ser libertados pelo osso subcondral, e contribuir para eventos catabólicos e 
sinovite.           
 A OA normalmente progride lentamente e pode permanecer assintomática por um 
longo período de tempo. Os sintomas clínicos, geralmente, ocorrem em estágios avançados 
da doença e incluem dor, rigidez, perda da função articular e incapacidade física. O 
diagnóstico da doença deve ser feito utilizando diretrizes clínicas que incluem o exame 
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clínico do doente, bem como a avaliação de alterações radiológicas na articulação, 
utilizando técnicas não-invasivas de imagem. Embora a combinação do exame clínico e 
radiológico seja essencial para o diagnóstico da OA, testes laboratoriais no SF, soro ou 
urina podem ser necessários para completar o diagnóstico. Esta abordagem bioquímica 
procura a existência de biomarcadores solúveis, que podem fornecer informações úteis 
sobre o estadio da doença e também prever o curso da sua progressão. Embora alguns 
biomarcadores para o diagnóstico da OA já estejam identificados, eles fornecem o 
diagnóstico em estágios avançados da doença, e atualmente não existem biomarcadores 
confiáveis, quantificáveis e facilmente mensuráveis que proporcionem um diagnóstico 
precoce e informações sobre o prognóstico. Assim, novos biomarcadores e testes 
diagnósticos são necessários para facilitar o diagnóstico precoce e subclínico, monitorizar a 
progressão e melhorar o prognóstico da OA.     
 Atualmente, ainda não há cura para a OA. O tratamento centra-se na redução dos 
sintomas, especialmente no controlo da dor, bem como na manutenção ou melhoria da 
mobilidade e função articular, de modo a melhorar a qualidade de vida dos doentes, mas 
não tem a capacidade de prevenir ou alterar a progressão da doença. Tipicamente, o 
controlo da OA combina terapias farmacológicas e não farmacológicas. O tratamento 
padrão começa com terapias não farmacológicas para aliviar os sintomas e restaurar a 
função articular. No entanto, muitas vezes estas terapias oferecem um alívio limitado dos 
sintomas, pelo que o tratamento farmacológico com drogas orais ou tópicas, como 
analgésicos e anti-inflamatórios não esteroides (NSAIDs), e terapias intra-articulares são 
frequentemente empregues, especialmente para reduzir a dor, embora a sua utilização deva 
ser controlada e evitada durante longos períodos de tempo, uma vez que causam efeitos 
secundários adversos. Em estágios avançados de OA, nos quais os doentes experimentam 
dor crónica e incapacidade motora, é frequentemente necessário submeterem-se a 
intervenções cirúrgicas que reduzem a dor e restauram a função articular, melhorando a 
qualidade de vida, mas não são capazes de curar a doença.   
 Investigação sobre a OA é essencial para uma melhor compreensão desta doença. A 
pesquisa baseia-se principalmente na compreensão de aspetos fisiopatológicos que 
permanecem desconhecidos, bem como na identificação de novos alvos terapêuticos, no 
desenvolvimento de agentes terapêuticos modificadores da doença e de novos marcadores 
bioquímicos para o diagnóstico, e na construção de um prognóstico para a doença. Uma 
vez que não existe um modelo ideal que represente a articulação osteoartrítica e simule 
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perfeitamente os eventos de ocorrência natural desta doença, vários modelos in vitro e in 
vivo são usados para estudar a OA. Os modelos in vitro são bons sistemas para o estudo de 
OA, uma vez que são geralmente menos dispendiosos do que os modelos in vivo, são 
fáceis de manipular, seguem a filosofia de refinação, redução e substituição do uso animal, 
e evitam questões éticas. Estes modelos são ferramentas importantes para o estudo 
preliminar da biologia da OA, bem como para a conceção, teste e validação de potenciais 
fármacos. Os modelos in vitro incluem culturas de células primárias, co-culturas, cultura 
de explantes de tecido e culturas 3D. Modelos in vivo são modelos animais que 
manifestam a doença espontaneamente ou quando induzidos, e representam um importante 
complemento aos estudos da OA realizados utilizando modelos in vitro. Eles fornecem 
uma reflexão mais precisa da ocorrência natural da doença nas articulações, permitindo 
acompanhar a progressão da OA desde estágios iniciais até estágios avançados. Dos 
modelos in vivo fazem parte modelos espontâneos como modelos de ocorrência natural e 
modelos geneticamente modificados, modelos induzidos cirurgicamente ou quimicamente, 
e modelos não invasivos.         
 Dado que os atuais fármacos utilizados no tratamento da OA não são capazes de 
prevenir, retardar ou parar a progressão da doença, tendem a ser caros e, normalmente, 
causar efeitos secundários indesejáveis, a pesquisa de novos fármacos com propriedades 
analgésicas, anti-inflamatórias e modificadoras da doença, e sem efeitos adversos, é 
extremamente importante para o tratamento da OA. Um número considerável de estudos 
tem sido feito para desenvolver ou encontrar novos agentes farmacológicos capazes de 
modificar ou retardar a progressão desta doença. Estes compostos são conhecidos como 
fármacos osteoartríticos modificadores da doença (DMOADs). No entanto, até ao 
momento ainda não existem DMOADs licenciados, embora vários agentes estejam sob 
investigação e já tenham mostrado resultados promissores. Os produtos naturais são 
também uma potencial fonte de agentes terapêuticos promissores para o tratamento da OA. 
Nas últimas décadas, vários compostos foram submetidos a estudos pré-clínicos e ensaios 
clínicos para avaliar os seus potenciais efeitos terapêuticos nesta doença. Os resultados 
revelaram vários compostos naturais com efeitos terapêuticos na OA, e alguns estão 
atualmente disponíveis no mercado como suplementos para o controlo da doença. 
Compostos naturais como a glucosamina, o sulfato de condroitina, extratos de Boswellia 
serrata, S-Adenosilmetionina (SAMe), insaponificáveis de abacate/soja, extratos de 
curcuma domestica, Lyprinol®, Aquamin® e Maritech® têm demonstrado, em ensaios 
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clínicos, ser tão eficazes como os NSAIDs no tratamento sintomático da OA, mas mais 
seguros que estes fármacos, uma vez que são bem tolerados pelo organismo e parecem não 
causar quaisquer efeitos adversos. Alguns compostos, como a glucosamina, o sulfato de 
condroitina, os insaponificáveis de abacate/soja e o resveratrol, também mostraram 
resultados promissores como DMOADs. Outros compostos naturais, como a cordicepina, a 
diosgenina, o ácido betulínico, a astaxantina, e o carnosol, atualmente em pesquisa pré-
clínica, demonstraram atividade anti-inflamatória em modelos de estudo de OA in vitro, o 
que sugere o seu potencial terapêutico para o tratamento desta doença.   
 As algas castanhas do género Cystoseira compreendem cerca de 50 espécies 
distribuídas mundialmente por águas subtropicais, com a maior diversidade de espécies e 
abundância encontrada no Mar Mediterrâneo e ao longo das costas do Atlântico Nordeste. 
Estas algas são uma fonte prolífica de meroditerpenóides, metabólitos secundários de 
biogénese mista, cujas estruturas são formadas por um núcleo de toluquinol ligado a uma 
porção diterpenóide. Os meroditerpenóides das algas do género Cystoseira foram descritos 
como tendo propriedades citotóxicas, antibacterianas, antivirais e antioxidantes. Relatos 
recentes de novos metabólitos produzidos pela Cystoseira incluíram outros tipos de 
bioatividades, como propriedades anti-inflamatórias. Recentemente, de los Reyes et al. 
isolou doze novos meroditerpenóides juntamente com oito compostos conhecidos de 
Cystoseira usneoides, uma espécie de algas castanhas do género Cystoseira, colhida na 
costa de Tarifa (Espanha). Dos produtos naturais isolados, cinco deles, identificados como 
meroditerpenóides (cistodiona G, cistodiona M, cistona C, 11-hidroxiadionadiona e 
amentadiona), mostraram uma significativa atividade anti-inflamatória in vitro, através da 
inibição da produção da citoquina pró-inflamatória TNF-α em macrófagos THP-1 
estimulados com lipopolissacárido (LPS). Estes achados sugerem claramente que estes 
compostos bioativos marinhos podem ser úteis na terapêutica de doenças inflamatórias e 
levaram-nos a explorar o seu potencial como novos agentes terapêuticos para a OA. Para 
tal, foram selecionados três dos meroditerpenóides que mostraram significativa atividade 
anti-inflamatória in vitro no estudo de de los Reyes et al. (amentadiona (YP), cistodiona G 
(Cyd G) e 11-hidroxiamentadiona (Cyd K)) e foi avaliado o seu potencial anti-
inflamatório, utilizando modelos de inflamação in vitro, como uma cultura de macrófagos 
THP-1 estimulada com LPS e hidroxiapatite (HAP), um sistema de células primárias 
articulares humanas (condrócitos e sinoviócitos) estimuladas com IL-1β, e um modelo de 
co-cultura de explantes de cartilagem articular saudável ex vivo e sinoviócitos primários 
vii 
 
 
estimulada com IL-1β. Foi demonstrada a atividade anti-inflamatória dos 
meroditerpenóides amentadiona (YP), cistodiona G (Cyd G) e 11-hidroxiamentadiona 
(Cyd K) em condições inflamatórias induzidas por cristais de cálcio. Também foi mostrada 
a atividade anti-inflamatória do meroditerpenóide YP no sistema de células primárias 
articulares humanas estimuladas com IL-1β.       
 Para futuramente estudar a OA e testar e validar novos fármacos para o tratamento 
desta doença, nesta tese, começámos a desenvolver um modelo 3D de OA in vitro/ex vivo, 
que recrie o sistema articular humano e as condições observadas na doença. Os estudos 
preliminares demonstraram que explantes de cartilagem articular saudável são capazes de 
recriar in vitro/ex vivo as condições inflamatórias e mineralizantes observadas na OA. Foi 
também mostrado que estes explantes de tecido cartilagíneo são capazes de recriar as 
condições inflamatórias de OA numa co-cultura com sinoviócitos primários.  
 Em conclusão, os nossos resultados sugerem o potencial terapêutico do 
meroditerpenóide YP na OA, e fornecem passos iniciais para o desenvolvimento de um 
modelo 3D de OA que permita o estudo da doença e o teste e validação de novos fármacos 
para o seu tratamento. 
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I. Literature Review  
 
 
1.1 Osteoarthritis 
 
Osteoarthritis (OA) is a chronic and progressive degenerative joint disease [1]. It 
represents the most common form of arthritis and is one of the most common diseases 
worldwide, affecting a large number of people, essentially elderly [1-3].   
 OA is a very complex disease that affects the whole joint [4]. Pathologic changes 
observed in OA joints include progressive degradation of the articular cartilage, synovial 
inflammation, bone hypertrophy, extracellular matrix mineralization, ligamentous laxity, 
meniscal degeneration and thickening of the joint capsule. These events lead to chronic 
pain, stiffness, deformity and consequently to the loss of joint function and permanent 
disability, culminating in severely impaired life quality [1, 2, 4-6]. This disease can affect any 
joint, but is most frequent in the knee, hand, hip, spine and foot [7].  
 
1.1.1 Epidemiology 
 
OA is one of the most frequent chronic diseases worldwide and one of the ten 
leading causes of disability in developed countries [8, 9]. Incidence and prevalence rates of 
OA increase with advancing age, especially from the age of 50, and although both genders 
develop the disease, women are more affected [7, 8, 10]. Data from the World Health 
Organization’s Scientific Group on Rheumatic Diseases estimates that 10% of the world’s 
population aged 60 years or older is affected by OA [11]. OA is an increasingly important 
public health problem. It is currently associated with excess mortality [12]. For these 
numbers contribute presence of comorbid conditions, adverse effects of drugs used to treat 
OA, particularly nonsteroidal anti-inflammatory drugs (NSAIDs), and reduced levels of 
physical activity, since OA is considered a major cause of morbidity, activity limitation, 
physical disability and reduced health-related quality of life [7, 10]. 80% of people with OA 
have limitations in movement and 25% cannot perform their major daily activities of life 
[13]. Furthermore, the increase in life expectancy, ageing populations and lifestyle factors 
such as obesity, will result in an increase of incidence, prevalence and severity of OA, 
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being expected that, in 2020, OA will be the fourth leading cause of disability worldwide 
[1, 8, 14, 15]. 
 
1.1.2 Classification  
 
OA is classified in primary or secondary depending on whether or not there is an 
identifiable underlying cause of the disease [4]. OA is classified as primary or idiopathic in 
the absence of an extrinsic cause [2]. The most common and generally accepted theory of 
the pathogenic mechanisms of primary OA supports the cumulative effects of continuous 
mechanical wear on articular cartilage, resulting in continuous microtrauma and repetitive 
damage of the cartilage extracellular matrix [2].  Secondary OA is classified by the presence 
of extrinsic factors which favour the disease development [4]. These factors include 
congenital or developmental disorders of joints; mechanical defects (limb length 
discrepancy, malalignment, hyperlaxity, meniscus lesions); inflammatory disorders 
(rheumatologic diseases, as rheumatoid arthritis and all chronic forms of arthritis); intra-
articular infections; trauma (injury to joints or ligaments, postsurgical); metabolic 
(haemochromatosis, articular gout, calcium crystal deposition) and endocrine disorders 
(diabetes, hypothyroidism, obesity) [2, 4].  
 
1.1.3 Risk Factors 
 
OA is a multifactorial disorder that usually results from both modifiable and non-
modifiable systemic and local factors within the joint [8, 16]. These factors may contribute to 
the disease pathogenesis, both to the development and progression in different 
compartments of the joint [2]. While systemic risk factors may act by increasing the 
susceptibility of joints to injury, across direct damage to joint tissue or by impairing the 
process of repair in damaged joint tissue, local risk factors are essentially biomechanical in 
nature and negatively affect the forces applied to the joint [17]. The major systemic and 
local risk factors for OA are listed in Table 1.1. However, the relative importance of risk 
factors varies for different joints and according to the stages of the disease [8]. Modify or 
prevent the risk factors is required to reduce the risk of OA and subsequent pain and 
disability. 
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Table 1.1 Main risk factors for OA. 
 
Systemic Risk Factors 
Age [16] 
Gender and Hormones [16] 
Race and Ethnicity [16] 
Genetics [16] 
Nutrition [16, 18] 
Local Risk Factors 
Biomechanics factors [16, 17] 
Overweight and obesity [16, 18] 
Injury/surgery [16] 
Occupation [8] 
Physical activity/sports [8] 
            
     
1.1.4 Pathophysiology 
 
The joints are complex structures where different connective tissues functionally 
cooperate to allow movement between the bones of the skeleton and simultaneously 
limiting the degree and axes of movement, allowing a correct functioning and integrity of 
these structures [1, 2].           
 The synovial joints, also known as diarthrodial joints or diarthrosis, are the most 
common type of joints in the mammalian body [19]. These joints are distinguished from 
other joint types because they are freely movable and contain a joint cavity with synovial 
fluid (SF) that lubricates the joint, allowing a soft movement between the adjacent bones 
[19]. Other structures present in these joints are articular cartilage surfaces, subchondral 
bones, joint capsule, synovial membrane and ligaments [2, 19]. Together these structures 
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work to maintain joint homeostasis [1].         
OA is characterized by changes in various tissues within synovial joints, with main 
pathological characteristics including articular cartilage degeneration, synovial 
inflammation and subchondral bone remodelling [2]. The pathophysiology of this disease 
involves a combination of biomechanical, cellular and biochemical processes in articular 
cartilage, synovial membrane and subchondral bone that collectively damage joint 
compartments and contribute to OA progression [2].  
 
 
Figure 1.1 Schematic representation of the main structures of a healthy and OA synovial joint. On the 
left, are represented the main structures of a healthy synovial joint: articular cartilage, synovial membrane, 
subchondral bone, joint capsule and joint cavity. On the right, are displayed the main changes in these 
structures found in OA. These include the degeneration of the articular cartilage, inflammation of the 
synovial membrane, subchondral bone remodelling and joint capsule thickening. Adapted from [2]. 
 
1.1.4.1 Articular Cartilage 
 
Articular cartilage is a highly specialized connective tissue with 2 to 4 mm 
thickness, and with unique viscoelastic proprieties. [20] This tissue covers and protects the 
ends of bones in synovial joints and provides a smooth and lubricated surface which 
facilitates the transmission of loads with a very low frictional coefficient, as well as the 
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cushioning of the underlying bones, allowing an efficient sliding movement during the 
joint motion [5, 20, 21]. It lacks blood vessels, lymphatics, and nerves, using adjacent tissues 
(subchondral bone and synovial membrane) to provide essential nutrients and remove 
metabolic products of cartilage, in order to maintain its health and integrity [20, 22].   
Articular cartilage is composed of an extracellular matrix (ECM) corresponding to 
more than 95% of its volume, and highly specialized cells, the chondrocytes, scarce and 
interspersed in between the abundant ECM [2, 20]. Structurally, it is divided into four 
different zones:  superficial zone, middle zone, deep zone, and calcified zone [20]. 
Chondrocytes and ECM components vary in number, size and orientation, depending on 
the anatomical regions of the articular cartilage [20].      
 The ECM is the functional element of the articular cartilage, providing the 
mechanical properties of the tissue [2]. ECM is composed of water, an abundant network of 
collagens and proteoglycans, and several other classes of molecules, such as lipids, 
phospholipids, non-collagenous proteins and glycoproteins, present in minor amounts [20, 
23]. Water is the most abundant component of articular cartilage, contributing 
approximately to 80% of the total weight [20]. The flow of water through and across the 
articular cartilage helps in the transport and distribution of nutrients to chondrocytes, as 
well as the lubrication of the joint [20]. Collagen is the most abundant structural 
macromolecule in ECM, corresponding to approximately 60% of the dry weight of 
cartilage [20]. Type II collagen is the major matrix protein found in articular cartilage 
representing 90% to 95% of the collagen in ECM [20]. Other collagens, such as collagen 
types I, IV, V, VI, IX and XI, although present in smaller amounts in cartilage, help to 
form and stabilize the type II collagen fibril network [20]. These macromolecules promote 
tensile strength in articular cartilage [2]. Proteoglycans are the second most abundant group 
of macromolecules in the ECM and represent 25% to 35% of the dry weight [20, 24]. They 
are composed of a protein core with one or more linear highly sulphated 
glycosaminoglycan chains covalently attached, which increases their water retention and 
makes the cartilage elastic and resistant to compression [2, 20, 23]. In articular cartilage exists 
a variety of proteoglycans, including aggrecan, decorin, biglycan, lumican and 
fibromodulin, essential for the normal functioning of the tissue [20, 23]. The most abundant is 
the aggrecan, which contributes to the physical properties of cartilage [23]. Remaining 
proteoglycans in cartilage, although in smaller amounts, have an important role in its 
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development and maintenance [20, 23].       
 The chondrocytes are the only resident cell type in articular cartilage, and 
represents about 2% of the total tissue volume [20]. They are highly specialized and 
metabolically active cells which play an important role in maintaining homeostasis of 
articular cartilage, since they are responsible for the development and maintenance of the 
ECM [2, 20]. They promote the synthesis of ECM components, such as proteins and 
glycosaminoglycan chains, and of degradative enzymes, such as matrix metalloproteinases 
(MMPs), a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS), 
and cathepsins, maintaining the dynamic equilibrium between synthesis and degradation of 
the ECM [20, 25, 26].        
In OA, marked alterations occur in the composition, structure and function of the 
articular cartilage [22]. Phenotypic changes of chondrocytes and degradation of ECM are 
central features of the articular cartilage degeneration [26].    
 Although there are several risk factors that can trigger OA, the main causes which 
initiates articular cartilage degeneration is cellular overstress or excessive mechanical load 
[2]. In early OA, chondrocytes begin to secrete Interleukin 1β (IL-1β) and Tumour Necrosis 
Factor α (TNF-α), the two major pro-inflammatory cytokines involved in OA onset and 
progression [27]. These pro-inflammatory cytokines supress collagen and proteoglycan 
synthesis required to maintain the ECM, and increase the synthesis of ECM-degrading 
enzymes, essentially collagenases (MMPs) and aggrecanases (ADAMTS) that begin the 
degradation of ECM [4, 25]. However, in an attempt to maintain the tissue, chondrocytes 
become most active, increase cell proliferation, create “chondrocyte clusters”, and increase 
the metabolic activity, which increases the synthesis of ECM components [28]. 
Nevertheless, the anabolic response of the chondrocytes is insufficient, and an imbalance is 
generated between synthesis and degradation of the ECM, leading to progressive 
degradation of the articular cartilage ECM [29]. The first ECM component to be degraded is 
aggrecan, by the action of aggrecanases namely ADAMTS-4 and, especially, ADAMTS-5 
[25]. Next, collagen degradation takes place by the action of several MMPs, such as MMP-
1, MMP-3 and MMP-13 [25]. MMP-3 is essentially expressed in early OA, and participates 
in the activation of MMP-1 and MMP-13, that actively contribute to cleavage collagen in 
ECM during OA [25]. MMP-13 is the major responsible for articular cartilage ECM 
degradation, since not only degrades type II collagen, but also others collagen types, 
aggrecan, and various other ECM proteoglycans and constituents [3, 21, 25]. While lost of 
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aggrecan can be reversed, collagen degradation is irreversible, and articular cartilage 
cannot be repaired when collagen is lost, leading to the progressive loss of articular 
cartilage ECM during OA progression [25]. Additional pro-inflammatory cytokines secreted 
by chondrocytes, such as Interleukin 6 (IL-6) and Interleukin 7 (IL-7), also contribute to 
catabolic events in articular cartilage [22, 27]. Both mechanical stress and inflammatory 
mediators induce intracellular signaling pathways, including the nuclear factor-kappaB 
(NF-kB) and mitogen-activated protein kinase (MAPK) pathways, which induce the 
expression of downstream target genes such as inducible Nitric Oxide Synthase (iNOS), 
Ciclo-oxigenase-2 (COX-2) and MMPs [27, 30]. iNOS induces the production of nitric oxide 
(NO) and COX-2 induces the production of Prostaglandin E2 (PGE2) [31]. Both promote 
articular cartilage ECM degradation [31]. Also, the reactive oxygen species (ROS) are 
implicated in the process of articular cartilage ECM degradation in OA, since it contributes 
to the reduction of ECM components and the increase of pro-inflammatory cytokines and 
MMPs [2, 32].           
 During OA progression, chondrocytes undergo phenotypic changes caused by 
inflammation and altered biomechanical environment in articular cartilage, starting to 
show a phenotype of terminally differentiated cells (hypertrophy and apoptosis) [33]. 
Apoptotic death of chondrocyte begins in superficial zone of the articular cartilage, and as 
the disease progresses it occurs also in middle and deep zones [26]. Hypertrophic 
chondrocytes contribute to the process of ECM degradation through the expression of 
ECM-degrading enzymes, especially MMP-13 [33]. 
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Figure 1.2 Degeneration of articular cartilage in OA. Articular cartilage undergoes structural and 
compositional changes during OA. a) Healthy articular cartilage is divided into four anatomical zones. 
Superficial zone (SZ) is thin, and has collagen fibers packed tightly and aligned parallel to the articular 
surface and small and flat chondrocytes in relatively high number. Middle zone (MZ) contains proteoglycans 
and thicker collagen fibrils organized obliquely to the articular surface, as well as spherical chondrocytes 
randomly distributed. Deep zone (DZ) contains largest diameter collagen fibrils in a radial disposition, 
highest proteoglycan content, and chondrocytes in columnar orientation, parallel to the collagen fibers and 
perpendicular to the joint line. Calcified zone separates the subchondral bone of the articular cartilage, and 
has collagen fibrils anchored of the deep zone up to subchondral bone and chondrocytes scarce and 
hypertrophic. Tide mark defines the interface between the deep zone and calcified zone. b) In early OA stage, 
changes in ECM include hydration, loss of proteoglycans and loosening of collagen network. The tissue 
breakdown begins at the articular surface, where fibrillation and fissures are observed in ECM. There is death 
of chondrocytes in the superficial zone. In middle zone, the proliferation of chondrocytes leads to the 
formation of so-called “chondrocyte clusters.” Some chondrocytes begin to undergo phenotypic changes and 
become hypertrophic. c) In advanced OA stage, the changes progress to dehydration, further loss of 
proteoglycans and degradation of the collagen network, extensive fibrillation and cartilage thinning. 
Hypertrophic chondrocytes undergo apoptosis. d) In end OA stage, all cartilage has been eroded, leading to 
denudation of the subchondral bone. Histological images stained with Safranin O. Adapted from [34 - 36]. 
 
Hypertrophic chondrocytes also contribute to the articular cartilage ECM 
calcification, a feature consistently associated to OA severity [33, 37]. Hypertrophic 
chondrocytes induce the expression of type X collagen in lower deep zone and calcified 
zone of articular cartilage [31]. This collagen type contributes to articular cartilage ECM 
calcification, since it contributes to the calcium-containing crystals deposition process [28, 
38]. The calcium-containing crystals deposited in the ECM are, essentially, basic calcium 
phosphate (BCP) crystals, a heterogeneous group of apatite crystals that include 
hydroxyapatite (HAP), octacalcium phosphate and tricalcium phosphate [39]. Moreover, 
hypertrophic chondrocytes undergo apoptosis that also contributes to the calcium-
containing crystals deposition in the ECM of articular cartilage [33].    
 In fact, the articular cartilage ECM calcification can occur not only owing to 
terminally differentiated chondrocytes but also due to many other factors namely the 
dysregulation inorganic pyrophosphate (PPi) and inorganic phosphate (Pi) metabolism, the 
imbalance between inhibitors and promineralizing factors, or to changes in extracellular 
Ca2+ levels [6, 37]. Loss of proteoglycans of ECM also favours the articular cartilage 
calcification process, since proteoglycans are potent mineralization inhibitors [37]. 
 Furthermore, the BCP crystals, particularly HAP that is the main mineral associated 
with OA, contributes to the articular cartilage ECM degradation process, by inducing the 
chondrocytes to produce pro-inflammatory cytokines, MMPs and NO [37]. Thus, calcium-
containing crystals play an important role in the onset and progression of OA, contributing 
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both in degradation and calcification of articular cartilage ECM [37]. 
 
1.1.4.2 Synovial Membrane 
 
The synovial membrane that coats the joint cavity is another important structure 
that contributes to the normal functioning of the synovial joints [1, 2]. This tissue is 
externally limited by a fibrous joint capsule that defines the joint cavity and holds the 
bones together [1]. Synovial membrane acts as a semipermeable membrane that controls 
molecular traffic into and out of the joint space and maintain the composition of SF [22].  
 Anatomically, synovial membrane consists of two layers: subintima and intima [40]. 
The subintima is a fibrous and supportive outer layer [40]. The intima is the inner layer 
directly next to the joint space, and consists of a thin layer of cells with phenotypic features 
of fibroblasts and macrophages [22, 40]. Fibroblast-like synoviocytes play a crucial role in 
the nutrition of the articular cartilage [2]. These cells also produce and secrete into the SF 
large amounts of important mediators (cytokines and growth factors), matrix degrading 
enzymes, as well as hyaluronic acid (HA) and lubricin, that contributes to lubricate the 
joint surface [2, 22]. Macrophages remove undesirable substances of chondrocytic 
metabolism from the SF [22, 40]. Together these factors contribute to protect and maintain 
the unique properties of articular surfaces and the integrity of synovial joints [22].  
       
In the course of OA, some histological changes occur in the synovial membrane [41]. 
Synovial inflammation (synovitis) is a common feature associated with the disease [41]. The 
early articular cartilage ECM degradation events may play a driving role in the 
development of inflammation within the OA joint and specifically in OA synovial 
membrane [42]. Once initiated the articular cartilage ECM degradation process, the 
degradation products are released into the SF and synovial membrane undergoes changes, 
becoming hypertrophic and hyperplasic, with an increase in the number of synovial lining 
cells that become active, proliferate and phagocyte these products [2, 41]. As the disease 
progresses, these histological changes are often accompanied by neoangiogenesis, fibrosis 
and infiltration of immune cells, such as macrophages and lymphocytes [22, 41]. 
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Figure 1.3 Histological features of synovial membrane in OA. In OA, the synovial membrane undergoes 
structural and compositional changes generally indicative of synovitis. a) Healthy synovial membrane is 
composed of two layers: a thin lining layer (intimal layer) and a loose connective tissue sublining layer 
(subintimal layer). b) OA synovial membrane undergoes changes such as synovial lining hyperplasia, fibrosis 
and immune cells (macrophages and lymphocytes) infiltration. Histological images stained with hematoxylin 
and eosin. Adapted from [2, 43]. 
 
Infiltrating immune cells and activated fibroblast-like synoviocytes are responsible 
for the synthesis and release into the SF of soluble inflammatory mediators, such as 
cytokines and chemokines [5, 41]. These mediators will induce synovitis in OA, as well as 
the production of catabolic mediators which together with pro-inflammatory cytokines and 
chemokines contribute to phenotype of terminally differentiated chondrocytes and cartilage 
ECM breakdown, creating a positive feedback loop in the articular cartilage degeneration 
[5, 31, 41]. Synovial macrophages are mainly responsible for the synthesis and release of IL-
1β, TNF-α and Interleukin 15 (IL-15), in SF [41]. High levels of IL-15 are released to SF, in 
early OA, and stimulate MMPs production and recruitment, survival and activity of T 
lymphocytes [41]. T lymphocytes, in turn, produce Interleukin 17 (IL-17), which induces 
chemokines production, such as Interleukin 8 (IL-8), by both fibroblast-like synoviocytes 
and chondrocytes, and in synergy with IL-1β and TNF-α promotes the propagation of 
synovitis and catabolic events in articular cartilage [5, 41]. BCP crystals are also present in 
synovial membrane and SF, and are able to induce synoviocytes proliferation and synovitis 
in OA [37]. 
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Figure 1.4 Inflammatory process in OA. Synovial membrane actively contributes to the inflammatory and 
catabolic events observed in the OA pathophysiology. Synovial and immune cells, such as macrophages and 
lymphocytes, produce pro-inflammatory mediators, including pro-inflammatory cytokines, that cause 
synovitis in OA joint and induce the production of ECM-degrading enzymes responsible for articular 
cartilage destruction. Synovitis stimulates chondrocytes production of pro-inflammatory mediators which 
also actively contribute to the destruction of cartilage. Products of cartilage breakdown are released in SF and 
contribute to the amplification of synovitis, creating a positive feedback loop of the inflammatory and 
catabolic events in OA. Adapted from [44]. 
 
Thus, pro-inflammatory cytokines, chemokines and ECM-degrading enzymes, 
present in SF, activate synovial cells and chondrocytes, contributing to a vicious positive 
feedback loop of articular cartilage degradation and synovitis [41].  Furthermore, changes in 
the synovial membrane observed in OA lead to changes in its permeability, which 
contributes to the decreased concentrations of HA and lubricin in SF, adversely affecting 
articular cartilage integrity [22]. 
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1.1.4.3 Subchondral Bone 
 
Other structure present in synovial joints is the subchondral bone. It defines the 
shape of joint and of the articular surfaces, restricts the mechanical deformation, and 
together with articular cartilage determines the absorption properties during movement [2, 
20]. Since subchondral bone is a highly vascularized tissue, it also provides nutrition to the 
avascular articular cartilage and contributes to the removal of metabolites and matrix 
degradation molecules contributing to articular cartilage integrity and for normal synovial 
joints function [45].           
    
Despite subchondral bone is an important mechanical damper, protecting the 
articular cartilage from some injury or mechanical stress, it has an important role in OA 
pathology [46]. As articular cartilage and synovial membrane, the subchondral bone also 
undergoes changes during the disease [10]. Nevertheless, it is not yet clear whether changes 
in subchondral bone precede changes in the articular cartilage and are a risk factor for OA, 
or whether subchondral bone changes are secondary adaptation processes after changes in 
the biomechanical properties of the overlying articular cartilage [2]. In early OA, 
subchondral bone shows significant changes such as the increased thickness of the 
subchondral bone plate and adjacent bone trabeculae [2]. As the disease progresses, initiates 
a bone remodelling process in areas of articular cartilage destruction, which results in the 
release of bone detritus in the SF within the joint space contributing to the inflammatory 
state in OA [2, 5]. Bone remodelling is associated with severe thickening (sclerosis) in the 
subchondral bone plate and consequent joint space narrowing, subchondral cysts, and 
osteophyte formation [45]. Subchondral cysts commonly arise in areas of total articular 
cartilage destruction [2]. Osteophytes are new bone structures formed on the margins of 
joints, derived from mesenchymal precursor cells within periosteal or synovial tissue [2, 4]. 
They result from an attempt to improve the congruence of the articular cartilage surfaces 
and contribute to stabilize the joint rather than contributing to OA progression [4, 5]. 
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Figure 1.5 Subchondral bone remodelling in OA. In the course of OA, subchondral bone undergoes 
remodelling process that actively contributes to OA pathophysiology. The main changes observed in the 
subchondral bone are subchondral bone sclerosis and cysts, and osteophytes formation. Associated with these 
structural changes in the subchondral bone is also joint space narrowing. Adapted from [47, 48]. 
 
Subchondral bone is also a source of inflammatory mediators implicated in the 
inflammatory process of OA and in the deep layer degradation of articular cartilage [46, 49]. 
Inflammatory mediators include pro-inflammatory cytokines and ECM-degrading 
enzymes, such as MMP-1, MMP-3 and MMP-13, and can be induced, for example, by 
vascular invasion of bone marrow tissue into the subchondral region when microfractures 
occur in the subchondral bone and calcified cartilage, caused by excessive load, or by 
inflammatory process in OA joint [49]. Also, in end-stage OA, BCP crystals can be released 
by subchondral bone and contribute to synovitis and catabolic events in OA [37].  
 
In short, OA can be considered a self-sustaining disease [29]. Once the initial 
damage in articular cartilage is done, fragments of articular cartilage ECM are produced 
and released into the joint space, stimulating synovitis in synovial membrane and 
consequently the production and release of pro-inflammatory mediators, such as cytokines 
and chemokines in SF, which in turn causes inflammation in the joint. This inflammatory 
condition drives the articular cartilage ECM degradation and induces the production of 
14 
 
 
ECM-degrading enzymes and more inflammatory mediators by chondrocytes, 
synoviocytes and osteoblasts, perpetuating the inflammatory and catabolic cycle in OA 
joint, and leading to disease progression and to the destruction of the articular cartilage.  
 
1.1.5 Diagnosis 
 
OA, normally, progresses slowly over many years and may remain asymptomatic 
for a long time [17, 50]. Usually, the time that OA remains asymptomatic correspond to the 
early stages of the disease and the clinical symptoms only occur in more advanced stages 
[50].  
The OA diagnosis must be made using clinical guidelines that include clinical 
history and examination of the patient, and evaluation of radiological changes in the joint 
[4, 17].            
 The clinical examination of the patient should include the observation of symptoms, 
such as pain, stiffness, loss of joint function and physical disability, and the examination of 
signs, such as crepitus, swelling, reduced joint mobility and bony enlargement/deformation 
[7, 8]. Occasional effusion and variable degrees of synovitis in OA joint contribute to the 
symptoms, especially for pain, that although it is considered chronic, in early symptomatic 
stages arises only associated with activity and over time becomes more constant and 
severe, with intermittent intense episodes [8, 9, 22]. Changes in the subchondral bone also 
contribute to pain and disability in OA [2].       
 The radiological evaluation should be able to observe structural changes in OA 
joint [17]. The non-invasive imaging techniques are an important tool for observation this 
structural changes [20]. Radiography is one of those non-invasive imaging techniques and is 
the most objective method used to the morphological assessment of osteo-articular 
changes, such as joint space narrowing, osteophytes and subchondral bone sclerosis and 
cysts [8]. This technique also has some limitations because it does not allow to visualize 
some important joint structures, such as articular cartilage, and provides little evidence of 
the existence of synovitis and imaging of effusions [8]. More sensitive non-invasive 
imaging methods, such as magnetic resonance imaging (MRI), ultrasonography and 
arthroscopy allow the visualization of the all joint structure in detail and contribute to OA 
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diagnosis [16]. MRI is a good diagnostic method because it has ability to capture the 
integrity of tissues, including soft tissues [20]. This method allows the detection of focal and 
diffuse cartilage changes as well as other changes in joints, such as synovitis, meniscal 
disruption, subchondral marrow lesions [8]. Also, ultrasonography and arthroscopy allow to 
see joint changes such as synovitis, effusion and joint degeneration, although the “gold 
standard” method to synovitis detection is synovial histology [22, 41]. Nevertheless, given 
that this method requires an invasive biopsy that may not be applicable or acceptable to all 
patients, non-invasive imaging techniques are a good alternative diagnostic in these cases 
[41].  
 
 
Figure 1.6 Radiological evaluation of OA joint. Radiograph (A-B) and MRI (C-D) images of joint 
illustrating features of OA. Arrows show: A) joint space narrowing; B) osteophyte formation; C) synovitis; 
and D) subchondral cyst formation. Adapted from [5, 51]. 
 
Although the combination of clinical guidelines and radiological findings are 
essential for OA diagnosis, laboratory tests on SF, serum or urine may sometimes be 
necessary to complete the diagnosis [8]. This biochemical approach searches for the 
existence of soluble biomarkers, that may provide useful information about the OA state 
and also predict the course of the disease progression [50]. Despite the easy accessibility of 
serum and urine, biomarkers secreted or released from specific tissues or cell types in OA 
are highly diluted in these body fluids and their identification requires highly sensitive and 
reliable detection techniques which are not always available for diagnosis [52]. Thus, most 
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of the biomarkers used in the diagnosis of OA are detected in SF [52].   
 Biomarkers for OA diagnosis are related to the pathophysiological events that occur 
in this disease. Biomarkers of articular cartilage degeneration include proteolytic enzymes, 
such as MMPs (MMP-3, MMP-9 and MMP- 13) and ADAMTS (ADAMTS-4 and 
ADAMTS-5) presents in SF and serum, as well as articular cartilage degradation products, 
such as cartilage oligomeric matrix protein (COMP) in serum and C-telopeptide of type II 
collagen (CTX-II) and aggrecan fragments in urine [41, 53, 54]. Biomarkers of synovitis 
include cytokines, such as IL-1β, TNF-α, IL-6, IL-17 and Interleukin 18 (IL-18), 
chemokines such as IL-8, NO, among others, and synovial membrane degradation products 
[22, 53]. In turn, biomarkers of subchondral bone remodelling include bone formation 
markers, such as osteocalcin (OC) and alkaline phosphatase (ALP) in serum, and type I 
collagen pro-peptides and bone degradation markers such as type I collagen fragments in 
serum and urine [53]. Although these biomarkers for OA diagnosis are already identified, 
they provide the diagnosis in advanced stages of the disease, and currently there are no 
reliable, quantifiable and easily measured biomarkers that provide an early diagnosis and 
information on the prognostic [8]. Thus, new biomarkers and diagnostic tests are necessary 
that can facilitate earlier and sub-clinical diagnosis, monitor progression and improve 
prognosis of OA [8, 50, 55].  
 
1.1.6 Treatment 
 
Currently, there is still no cure for OA [56]. Current treatment is mainly focussed on 
the reduction of symptoms, especially in pain control, as well as in maintenance or 
improvement of joint mobility and function, in order to improve life quality of patients [4, 
8]. 
There are three types of different treatment modalities: non-pharmacological, 
pharmacological and surgical [4].         
 Typically, management of OA primarily should combine pharmacological and non-
pharmacological therapies [4]. Standard treatments begin with non-pharmacological 
therapies to relief the symptoms and restore joint functionality [1]. This can include weight 
loss, orthotic devices, regular exercise and physiotherapy, as for example, range-of-motion 
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exercises and muscle strengthening [1, 8]. Given that often these therapies offer very limited 
symptoms relief, pharmacological treatment with oral or topical drugs and intraarticular 
therapies, are frequently also employed especially to reduce pain [8]. For initial 
management of OA patients, pharmacological treatment recommended includes analgesics 
such as acetaminophen (Paracetamol) or Tramadol due to its safety and effectiveness [4]. 
However, if analgesics fail or are shown to be inefficient, NSAIDs are given as a second-
line of OA treatment [4]. These are effective anti-inflammatory and analgesic drugs often 
used for symptomatic OA treatment, which exert their effects by the inhibition of COX 
enzymatic activity and consequent blockade of prostaglandins synthesis, relieving 
symptoms as pain, swelling, and stiffness [57]. NSAIDs include oral and topical 
formulations. Some of the most widely prescribed NSAIDs worldwide, such as ibuprofen, 
naproxen, diclofenac, ketoprofen, indomethacin and piroxicam are available in both 
formulations [57]. However, ibuprofen and naproxen are mostly available in the oral 
formulation, while diclofenac is commonly used in topical formulation since reduce 
systemic exposure [4, 57]. Aspirin, celecoxib, oxaprozin are also widely used NSAIDs but 
are only available in oral formulation [57]. Nevertheless, NSAIDs should be taken in low 
doses and in a short-term in order to minimise the occurrence of several known adverse 
events, such as gastrointestinal ulcers and bowel lesions, cardiovascular thrombotic events, 
especially myocardial infarction, as well as renal and hepatic events [4, 57]. Dietary 
supplements, such as glucosamine sulfate and chondroitin sulfate, are also used because 
they have anti-inflammatory activity and the ability to relieve OA symptoms [4, 41]. Intra-
articular administered agents, such as anti-inflammatory corticosteroid injections and 
hyaluronate injections, are alternative options for the symptomatic treatment of OA and 
could be considered when the patients have moderate to severe pain and do not respond 
satisfactorily to oral analgesic/anti-inflammatory agents [4]. However, especially 
corticosteroids should be avoided whenever there are alternative therapies because its 
repeated use has several reported adverse effects such as, tissue atrophy, cartilage 
degeneration and joint destruction [4]. Potent opioids, although a therapeutic option for the 
OA treatment, should only be used for the treatment of severe pain and in patients who 
have an inadequate response to or are unable to tolerate the drugs mentioned above, since 
there is risk of adverse events [4]. Pharmacological and non-pharmacological therapies only 
relieve OA symptoms and improve joint function, not having the ability to prevent or alter 
their progression [1, 3].         
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 In advanced OA stages, in which patients experience intractable chronic pain and 
disability, is frequently necessary to undergo surgical interventions, such as correction 
osteotomy and arthroplasty [1, 4]. Correction osteotomy is a surgical intervention 
realignment to change the load pattern in the joint, and in arthroplasty an artificial device 
(prosthesis) is used to replace the joint and restore it functionally [1]. These surgical 
techniques reduce pain and restore joint function, improving the life quality of patients, but 
are not able to cure OA [1]. 
 
1.2 Study Models in Osteoarthritis  
 
Research on OA is essential for a better understanding of this disease [1]. The 
research is mainly based on the understanding of pathophysiological aspects that remain 
unknown, as well as in identification of new therapeutic targets, development of disease-
modifying therapeutic agents and novel biochemical markers for diagnosis, and 
constructing a prognosis for the disease [1, 2]. Since there is no ideal model that represents 
the OA joint and perfectly simulates naturally-occurring events in this disease, several in 
vitro and in vivo models are used to study OA [58]. These models are induced under 
experimentally controlled conditions to test parameters such as response to a load or to 
catabolic stimulus, and, thus, detect specific pathological hallmarks of disease [1, 58].  
 
1.2.1 In vitro models 
 
In vitro models are good systems for the OA study, since they are usually less 
expensive than in vivo models, easy to manipulate, follow the 3R philosophy of refining, 
reducing and replacing the animal use, and avoid ethical issues [58, 59].  These models are 
important tools for preliminary study of OA biology, as well as for the design, validation 
and testing of potential therapeutic drugs [58]. They use load based-methods to recreate the 
development of post-traumatic OA which occurs following an injurious articular load, and 
cytokines based-methods using cytokines, such as IL-1β and TNF-α, to recreate the 
inflammatory environment of the joint OA [58].  
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 In vitro models include primary cell cultures, co-cultures, tissue explants culture 
and three-dimensional (3D)-cultures [1].        
 Primary cells culture in monolayer represent one of the most widely used models 
for the OA study because they provide a simplified, focused, and cost-effective analysis [31, 
60]. This model can include the use of several primary cell types, such as chondrocytes, 
osteoblasts and synoviocytes, isolated from animal or human donor tissue [1]. The origin of 
these cells enables them to maintain characteristics more similar to their organs of origin, 
which allows these models to reproduce physiologically more significant results [59, 61].  
This model is essential to study the biology and biochemistry of cells involved in OA, but 
does not allow the study of the ECM and the dynamic processes involved in the in vivo OA 
pathology [31, 59]. Primary cell culture models are widely used in initial drug screening, for 
example for the evaluation of the compounds toxicity [62]. Nevertheless, these primary cells 
systems also have disadvantages. These include the difficulty to obtain a sufficient number 
of cells and also the diversity of cells within the cultures [1].    
 Co-culture is a more complex system that allows the study of the interactions 
between cell populations involved in OA [58]. It consists of a cell culture system in which 
two or more different cell populations or tissues are grown with some degree of contact 
between them [63]. The use of a co-culture model is fundamental to study the cell-cell 
interaction and to identify potential mechanisms relevant to the disease [63]. Lee et al. 
demonstrated that co-culture of injured cartilage and normal fibroblastic synoviocytes was 
associated with a protective effect of synoviocytes on the progression of an OA phenotype 
in injured articular cartilage [64]. Synoviocytes were shown to reduce the presence of 
markers of early OA in cartilage, such as focal cell loss and chondrocyte cluster formation, 
and to alter chondrocyte gene expression to favour anabolic activity [64]. In addition, this 
model is also relevant for OA drug research because it provides a more representative in 
vivo-like human model than monolayer cultured primary cells, and allows high-throughput 
testing and monitoring of the drug effects on cell–cell interactions [63].    
 Ex vivo tissue explant culture is another important in vitro OA model, using joint 
tissue samples as cartilage, synovial membrane or subchondral bone explants isolated from 
the human or animal organisms and cultured in experimentally controlled conditions [1]. 
This model preserves the original cell–cell and cell–matrix interactions, offering a unique 
opportunity to study these mechanisms in a setting where both the natural three-
dimensional organisation, as well as the cellular diversity is preserved [65]. Thus, ex vivo 
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tissue explant culture can be more physiological relevant than the two-dimensional primary 
cells, since they are able to closely mimic the in vivo processes [65]. They represent a 
valuable tool for studying inflammatory process and ECM cartilage degradation [58]. 
Grenier et al. developed an in vitro cartilage degradation model [66]. They used 
collagenase-treated cartilage explants and produced an ECM damage condition comparable 
to that seen in the OA early stages [66]. This model may be important for the study of the 
degenerative process of OA cartilage as well as for the design and testing of therapeutic 
strategies for OA.          
 Also, 3D-culture is a relevant in vitro model to study OA. In this model, one or 
more cell populations are cultured in a 3D biological or synthetic material, and grow 
naturally in a 3D environment that allows them to establish a cell-cell and cell-ECM 3D 
communication network, recreating the main functional and architectural features of tissue 
in vivo [61, 62]. The 3D structure not only influences the spatial organization of the cell 
surface receptors engaged in interactions with surrounding cells, but also induces cell 
physical constraints, which allows the study of cellular responses in a setting that more 
closely mimics the in vivo OA joint environment [62]. This model has a great potential for 
application in drug discovery for OA because it provides a physiologically relevant 
environment and predictive results for the in vivo clinical tests [62]. Sun et al. used an in 
vitro human 3D cartilage tissue system, consisting of primary chondrocytes cultured in silk 
protein porous scaffolds, to study the impact of inflammatory mediators on chondrocytes 
and matrices as an initial approach to simulate OA early stages [31]. The results revealed 
that this system mimicked the inflammatory environment of OA cartilage, since they 
observed OA-like features upon stimulation with cytokines and macrophage conditioned 
medium [31]. This in vitro OA tissue system can be useful for the study of OA formation 
and progression as well as for drug screening [31].  
Altogether the use of in vitro models clearly includes advantages and disadvantages 
that are summarized in the Table 1.2. 
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Table 1.2 Advantages and disadvantages of in vitro models used in the study of OA. 
 
 
 
 
 
Model  Advantages Disadvantages 
 
Monolayer 
culture 
 
Expansion of a cellular resource 
from a single sample [58] 
 
Testing several hypotheses from a 
single sample [58] 
 
Research of distinct pathways in 
isolation [58] 
Difficulty to obtain an adequate 
cell number [1] 
 
Phenotypic changes of isolated 
cells [58] 
Life span and cell proliferation is 
finite (i.e. limited to a cell 
divisions number) [59] 
Co-culture 
Cross-talk between cell types or 
tissues [58] 
Different cell types or tissues 
require different culture 
conditions, or compromise when 
cultured together [58] 
Tissue 
explant 
culture 
 
Easy to produce [58] 
Cells maintained in normal ECM [58] 
 
Cell-cell and cell-matrix interactions 
[1] 
 
Maintenance of tissue phenotype [1] 
 
 
 
Observation of ECM degradation [58] 
Limited number of samples from 
the same source [58] 
 
High inter-experimental variability 
[1] 
 
Cells at the explant edge die [58] 
 
Potential systemic influences on 
the tissue of interest [1] 
3D-culture 
Maintenance of tissue phenotype [1] 
 
Cell-cell and cell-matrix interactions 
[1] 
Cellular responses study in 3D 
environment [62] 
Cells types used have to be first 
isolated and expanded [58] 
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1.2.2 In vivo models 
 
In vivo models are animal models that manifest the disease spontaneously or when 
induced, and represent an important complement to the studies performed using in vitro 
models for OA [2, 67]. They provide a more accurate reflection of how the disease occurs 
naturally in the joints, allowing to follow the OA progression from the early to the late 
stages [1, 31, 58]. These models allow the study of pathological and metabolic factors, as well 
as of long-term transient changes in tissue structure and joint organization in OA [66]. 
Nevertheless, it should be kept in mind that there is no animal model of OA that accurately 
reflects all aspects of this complex human disease.       
Spontaneous models, including naturally-occurring and genetically-modified 
models, are mostly used to study primary OA [67]. Many mammalian populations are 
affected by OA, including humans and domesticated animal species, such as dog, horse, 
sheep, rabbit, guinea pig and mouse [58, 67]. Given that these animals naturally develop OA, 
the slow progression of the disease can simulate the natural progression of human primary 
OA, making these animals ideal naturally-occurring models for the OA study [67]. The most 
widely used naturally-occurring OA animal model is Dunkin Hartley guinea pig, described 
to best represent OA in humans, although naturally-occurring OA mouse models such as 
STR/ort mice, are also considered an acceptable animal model for studying the 
development of OA [67]. Genetically-modified models play a crucial role in understanding 
specific genetic contributions to the OA pathogenesis [67]. In these models, genetic 
modifications, such as transgenic expression of a gene, knock-out and knock-in strategies, 
inducible and tissue-specific gene expression, are induced and lead to the development of 
OA-associated genetic defects [1]. Transgenic mice have been a genetically-modified model 
extensively used to study OA [67].       
 Secondary OA is essentially studied using induced models. These models include 
surgically-induced or chemically-induced models that allow the study of OA to be 
performed in a short period [67]. Induced models have been used to study post-traumatic 
OA and to test the effect of drugs on the disease process [67]. Surgically-induced models are 
an excellent choice for short-term studies because they induce a rapid disease progression 
and are highly reproducible [67]. These models have been used to study the pathogenesis of 
post-traumatic OA, since they induced structural changes in the joints similar to those 
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observed in OA [67]. There is a large number of surgically-induced models that lead to OA 
changes in the joint, however the most commonly used include anterior cruciate ligament 
transection (ACLT), partial or total meniscectomy and medial meniscal tear [67]. ACLT is 
the most widely used model because with this method the OA lesions develop more slowly 
than with other surgical models, increasing the ease of use of this model in pharmaceutical 
studies [67]. Chemically-induced models essentially involve the injection of toxic or 
inflammatory compounds such as papain, sodium monoiodoacetate, quinolone or 
collagenase directly into the joint, causing OA changes in this structure [67]. Like 
surgically-induced models, these models are also easy to induce and highly reproducible, 
which makes them a good choice for short-term studies [67]. Furthermore, they are less 
invasive than surgical-induced models, avoiding the need for surgery as well as possible 
infections in some animals [67]. However, chemically-induced models cannot induce post-
traumatic OA [67]. Chemically-induced models are essentially used to study the effects of 
drugs on the inflammation and pain [67].       
 Non-invasive models are a viable alternative to induced models of OA [67]. These 
models are also used in animal such as mouse, dogs and rabbits, and do not require surgical 
or chemical intervention to induce OA, since injury is caused externally by mechanical 
equipment [67]. Furthermore, these models are highly reproducible and allow that the injury 
is created with precision, which is not always feasible in more invasive models [67].  
The main advantages and disadvantages of in vivo models for OA are summarized 
in Table 1.3. 
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Table 1.3 Advantages and disadvantages of in vivo models used in the study of OA. 
 
 
 
Given that one model is not sufficient to study all features of human OA, the 
combination of the various models may also be useful to increase the knowledge about 
disease [67]. Another possibility is the development of combinatorial models encompassing 
different physiological and molecular aspects of OA which should more accurately reflect 
the pathogenesis of the naturally-occurring disease [58]. 
 
Model  Advantages Disadvantages 
 
Spontaneous 
Natural development of OA 
[67] 
 
Slow OA progression 
simulating natural human OA 
[67] 
 
Animal has to be followed to 
maturity before OA develops [67] 
 
Needs time for the injury to 
develop [67] 
 
Expensive [67] 
 
Variability in the disease 
phenotype [1] 
Induced 
Disease rapidly induced [67] 
 
Easily reproducible [67] 
 
Disease manifestations less 
variables [1] 
 
No correlation to natural 
degenerative changes in human 
OA [67] 
 
Induction too quick to study early 
stages of OA development as 
well as early drug therapy [67] 
Non-invasive 
Disease rapidly induced [67] 
 
Easily reproducible [67] 
 
Used to study early changes 
and the effects of early 
therapeutic intervention [67] 
Equipment not universally 
available [67] 
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1.3 Research on novel therapeutics for Osteoarthritis  
 
Current OA treatment intervention strategies remain largely limited to analgesics 
and anti-inflammatory drugs which are focussed in pain relieve and maintenance of joint 
mobility and function. These drugs are not able to efficiently prevent, reduce or stop the 
OA progression and they tend to be expensive and, usually, cause undesirable side-effects. 
Research on novel and alternative drugs with analgesic, anti-inflammatory and 
chondroprotective properties, and without side-effects, is extremely important for the OA 
treatment.          
 Recently a considerable amount of research has been made to develop and find new 
pharmacological agents to modify or slow the progression of OA. These compounds are 
known as disease-modifying osteoarthritis drugs (DMOADs). Nevertheless, until know 
there are no licensed DMOADs although several potential agents are currently under 
investigation [68 - 71]. Some of them have shown promising results. Fibroblast growth factor 
18 (FGF-18) is a chondrogenic factor that promotes chondrocyte proliferation and 
stabilization of the anabolic chondrocyte phenotype [72]. Recently, a recombinant human 
fibroblast growth factor 18 (rhFGF-18) was able to increase proliferation of articular 
chondrocytes and significantly decrease glycosaminoglycan release and depletion from the 
cartilage of mouse femoral heads in culture, as well as prevent cartilage degradation in a 
surgical medial meniscus tear model in rat [73]. Also intra-articular rhFGF-18 injection was 
associated with a significant improvement in total femorotibial cartilage volume and joint 
space width, as well as symptom improvement in a randomized, double-blind, placebo-
controlled, multicenter clinical trial in patients with primary knee OA [72]. These findings 
suggest rhFGF-18 as a potential OA disease modifying therapeutic agent. MMPs have also 
been considered excellent targets for OA treatment [74]. However, clinical utility of broad-
spectrum MMP inhibitors developed for this purpose is restricted by dose-limiting 
musculoskeletal side effects observed in humans [74]. Baragi et al. have identified a new 
class of potent and selective MMP-13 inhibitors suitable as potential DMOADs, since this 
class of compounds induced blockage of cartilage collagen degradation and exerted 
chondroprotective effects, without inducing musculoskeletal toxicity in rat OA model [74]. 
In studies using the anterior cruciate ligament transection (ACLT) dog model, N-
iminoethyl-L-lysine (L-NIL), a potent and selective inhibitor of iNOS, decreased both 
26 
 
 
collagenase and metalloprotease activity in the cartilage and the levels of IL-lβ, PGE2, and 
nitrite/nitrate in synovial fluid, leading to a reduction in the size of the cartilage lesions, 
synovial inflammation, and number and size of osteophytes [75, 76].  Reduction of apoptotic 
chondrocytes was also observed [77]. Together, these findings demonstrated the 
effectiveness of the selective inhibitor of iNOS, L-NIL, in attenuating the OA progression 
in an experimental in vivo model, suggesting it as a potential DMOAD [75 - 77]. Also the 
calcitonin, despite being indicated for the prevention of osteoporosis, since it is responsible 
for the calcium homeostasis regulation, promotes osteoblastic bone formation and inhibits 
bone resorption, seems to play a therapeutic role in OA [71]. Manicourt et al. showed that 
calcitonin reduces the severity of the degenerative changes in articular cartilage in anterior 
cruciate ligament transection (ACLT) dog model, by reducing the size of the osteophytes 
and the grade and size of the cartilage erosions [78]. Recently, in a 2-year phase 3 multi-
center, double-blind, randomized placebo-controlled clinical trial in patients with knee OA, 
oral salmon calcitonin resulted in a significant symptom-modifying efficacy, by reduction 
of pain and stiffness and improvement of physical function, and in some structure-
modifying efficacy, by increase in cartilage volume [79]. Together, these studies indicate the 
potential of calcitonin as an OA disease modifying therapeutic agent, able to inhibits the 
structural OA disease progression and improve function.  
Natural products consist in secondary metabolites produced by terrestrial and 
marine plants, algae, animals and microorganisms [80]. They may also be a source of 
promising therapeutic agents for the OA treatment. Its role as medicines have been 
recognized since ancient times [81]. They are important sources of therapeutic agents for 
several human diseases, such as cardiovascular disease, cancer, and arthritis, and they are 
usually described to cause less or no side effects [80, 81]. Many of the pharmaceuticals 
commercially available are natural products or derivatives thereof  [82].   
 In addition, natural products are important sources of compounds for the discovery 
and development of new drugs [82]. This process starts with the preclinical stages of the 
drug discovery process [83]. The first and one of the most important steps in developing a 
new drug is target identification and validation [83]. A good target needs to be efficacious, 
safe, meet clinical and commercial needs, and be ‘druggable’, that is, to be accessible to 
the putative drug molecule and upon binding, elicit a biological response which may be 
measured both in vitro and in vivo [83]. Drug discovery process begins with identifying the 
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function of a possible therapeutic target and its role in the disease [84]. Target validation 
requires the demonstration that a molecular target is directly involved in a disease process, 
and that modulation of the target is likely to have a therapeutic effect [84]. After being 
identified, the target validation is performed using a validation techniques range, which 
includes in vitro tools, use of animal models, and modulation of a desired target in disease 
patients [83]. Following the process of target validation, compound screening assays are 
developed for hit identification and lead discovery phase [83]. Both cell-based assays and 
biochemical assays have been used successfully to identify hit and candidate molecules 
that show significant biological activity [83]. High throughput screening (HTS) is a 
screening strategy frequently used and involves the screening of the entire compound 
library directly against the drug target or a more complex assay system, such as a cell-
based assay [83].  Several hits are obtained from this process, and triage is essential to 
reduce, confirm and cluster hits into series [83]. The output of a compound screen is 
typically termed a hit molecule, which has been demonstrated to have specific activity at 
the target protein in a biochemical and/or cell based secondary assay [83, 84]. In hit-to-lead 
phase, the potency and selectivity of compounds is improved, and the pharmacokinetic and 
toxicity is assessed in animal models [83]. Lead optimization phase is the final preclinical 
stage of the drug discovery process [83]. Compounds at this stage are ready for final 
characterization before being declared as preclinical candidates [83]. In this phase the 
favourable properties are maintained and in lead compounds while deficiencies in the lead 
structure are improved in order to make it suitable candidates for clinical development [83].
 Compounds that have proven to be safe and effective in pre-clinical research, are 
selected to clinical research, which is performed in human volunteers, in four study phases, 
to evaluate how the compound interacts with the human body and confirm the pre-clinical 
research results [85]. In Phase 1 studies are focussed on collecting information about how 
the compound interacts with the human body [85]. The safety and dosage is tested, from 
adjusted dosage schemes based on animal data, to find out how much of a drug the body 
can tolerate and what are their acute side effects [85]. Early information about how effective 
the compound is also obtained, and will be crucial for the design of Phase 2 studies to 
determine to the form of drug administration in order to limit risks and maximize benefits 
[85]. Phase 2 studies provide additional safety data [85]. These studies evaluate the compound 
efficacy and more adverse effects [85]. These data are used to refine research questions, 
develop research methods, and design Phase 3 studies [85]. Phase 3 studies again evaluate 
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the compound efficacy and monitors adverse reactions, since this study is performed in 
larger patient groups and longer in duration [85]. This provide most of the safety data 
because the results are more likely to show long-term or rare adverse effects [85]. The 
compounds that successfully passes through of these three phases will be approved by the 
national regulatory authority for commercialization, and are tested in phase 4 studies 
involving safety surveillance (pharmacovigilance) to confirm the compound safety and 
efficacy [85]. 
  
1.3.1 Natural products as therapeutic agents for OA 
 
Given that natural products appear to be a good alternative to search for novel 
therapeutic agents for OA, in the last decades, several compounds have been subjected to 
pre-clinical studies and clinical trials to evaluate its potential therapeutic effects in this 
disease. The results have revealed several natural compounds with therapeutic effects in 
OA, and some are currently available on the market as supplements for the disease 
maintenance. 
 
1.3.1.1 Natural compounds with effect on symptomatic OA 
 
Several natural compounds, including marine compounds obtained from different 
marine sources such as molluscs and algae have been shown, in clinical trials, to have 
similar efficiency to NSAIDs in the symptomatic OA treatment but with greater safety, 
since they are well tolerated by the organism and do not seem to cause any side effects.  
Glucosamine (an aminosaccharide) and chondroitin sulphate (a glycosaminoglycan) 
are natural substances derived from animal cartilage and crab shells, and are naturally 
occurring constituents of articular cartilage proteoglycans [4, 86]. A double-blind clinical 
trial evaluated the efficacy and safety of glucosamine sulphate when compared to 
ibuprofen in patients with knee OA, and concluded that glucosamine sulphate is as 
effective as the NSAID ibuprofen in the symptomatic treatment of OA but significantly 
better tolerated [87]. The long-term effects of chondroitins 4 and 6 sulfate on the symptom 
changes associated with OA were also evaluated in a randomized, double-blind, placebo-
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controlled clinical trial in patients with knee OA where it was observed that chondroitin 
sulphate is safe, significantly reduces pain and does not cause serious side effects [88]. 
Together these results indicate that glucosamine sulphate and chondroitin sulphate are 
suitable for long-term OA treatment. Currently, these natural substances are available in 
the market and are widely used for the maintenance of symptomatic OA [86].  
Boswellia serrata is an ancient Indian medicinal plant whose gum resin is well-
known for its anti-inflammatory, anti-arthritic and analgesic properties [89]. The anti-
inflammatory and anti-arthritic efficacy of alcoholic and aqueous Boswellia extracts have 
been established in in vivo models, using mice and rat models, and in clinical trials [90 - 93]. 
In 2011, Vishal et al. conducted a double-blind, randomized, placebo-controlled clinical 
trial, in which they evaluated the action in the relief of clinical symptoms of OA and anti-
osteoarthritic efficacy of Aflapin®, a novel synergistic composition derived from 
Boswellia serrata gum resin that contains B. serrata extract enriched to 20% 3-O-Acetyl-
11-keto-beta-boswellic acid and B. serrata non-volatile oil [89]. They found that 
encapsulated Aflapin® significantly improves joint function and relieves pain at as early as 
5 days of treatment in OA subjects, without causing any significant side effect [89]. These 
results validate the potential anti-osteoarthritic  efficacy and safety of Aflapin® and 
corroborate the results of a previous clinical trial study [94], suggesting that Aflapin® 
confers quick and significant therapeutic action in OA subjects, and can be used as 
effective alternative therapeutic strategy for the management of OA in humans [89]. Other 
commercial formulations for the OA maintenance containing Boswellia serrata, such as 
Boswellin®, Shallaki® and Rheumatic-X®, are currently available on the market [95]. 
S-Adenosylmethionine (SAMe) is a metabolite of the amino acid methionine [96]. It 
is produced endogenously from methionine and adenosine triphosphate (ATP), and is an 
important physiologic compound distributed throughout the body tissues and fluids, since 
it is an important methyl group donor that play an essential role in many biochemical 
reactions involving enzymatic transmethylation [97]. It has anti-inflammatory and analgesic 
effects and is used as a dietary supplement in the management of OA symptoms [97, 98]. The 
majority of studies evaluating SAMe in the management of OA compare SAMe to 
NSAIDs, and conclude that SAMe appears to be of equivalent effectiveness to NSAIDs in 
reducing pain and improving functional limitations, with fewer side effects [97]. In 2004, 
Najm et al. performed a randomized, double-blind, cross-over trial to compare the 
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therapeutic effectiveness of SAMe to a COX-2 inhibitor (Celebrex®) for pain control, 
functional improvement and to decrease side effects in people with OA, and concluded that 
SAMe has a slower onset of action but is as effective as Celebrex® in the management of 
symptoms of knee OA [97]. In 2009, Kim et al. performed a multicenter, randomized, 
double-blind, Phase IV clinical trial to compare the therapeutic efficacy and tolerability of 
SAMe and Nabumetone, a frequently prescribed NSAID with a low risk of gastrointestinal 
adverse effects, in the relief of pain in patients with knee OA [98]. They found no significant 
differences in pain relief, tolerability or side effects between treatment with SAMe or 
Nabumetone, confirming that SAMe is as effective as NSAIDs in the OA treatment [98].  
Avocado/soybean unsaponifiables (ASU) are natural vegetable extracts composed 
of one third avocado and two thirds soybean unsaponifiables oils [99]. Preclinical in vitro 
studies using human articular chondrocytes, as well as in vivo studies using experimental 
OA animal models, such as mice, sheep and horse, have demonstrated that ASUs has 
beneficial effects on OA, as they have been shown to possess chondroprotective, anabolic, 
and anti-catabolic properties, as well as anti-inflammatory properties [99 - 104]. At the 
clinical level, ASUs are able to reduce pain and stiffness while improving joint function 
[99]. The symptomatic efficacy and safety of ASU in OA of the knee or hip, as well as the 
potential residual effects of ASU after stopping treatment were evaluated in a prospective, 
randomized, parallel-group, double-blind, placebo-controlled, multicenter trial in patients 
with primary OA [105]. The results showed significant symptomatic efficacy of ASU over 
placebo in the treatment of OA, which persisted for 2 months after the end of treatment 
[105]. ASU proved to be safe, since no severe side effects between ASU and placebo were 
noted in the present study [105]. These results suggest that ASU could help to reduce 
NSAID consumption in patients with symptomatic OA [105]. 
Curcumin (diferuloylmethane) is a low molecular weight polyphenol isolated from 
the rhizomes of the plant turmeric (Curcuma longa), an endemic species of India [81]. 
Several pre-clinical and clinical studies have shown that Curcumin has anti-inflammatory 
action, which supports its great potential for treating OA [81, 106]. Kuptniratsaikul et al. 
performed a double-blind randomized controlled clinical trial in which primary knee OA 
patients received ibuprofen or Curcuma domestica extracts, in order to determine the 
safety and efficiency of this natural compound in pain reduction and functional 
improvement compared with ibuprofen [107]. They observed that Curcuma domestica 
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extracts were as efficacious as ibuprofen in pain reduction and functional improvement, 
and that its side effect profile was similar but with fewer gastrointestinal side effects 
reports in the Curcuma domestica extracts group [107]. These results show that Curcuma 
domestica extracts are so effective as ibuprofen for the treatment of knee OA, but it 
induces fewer gastrointestinal side effects that the NSAID [107].   
Lyprinol® is a patented extract from the bivalve mollusc Perna Canaliculus [108]. 
The clinical efficacy and safety of this extract was evaluated in a multicenter trial in 
patients with symptomatic OA of the knee and hip, and the results showed that Lyprinol® 
significantly relieve pain and improve joint function, in addition to not causing side effects 
[108]. These results demonstrate that Lyprinol® was very effective product for the relief of 
signs and symptoms in OA [108]. 
Also, the therapeutic potential of formulations containing a blend of various marine 
natural products, such as Aquamin® and Maritech®, was evaluated in symptomatic OA. 
Aquamin® is a multi-mineral supplement derived from the red algae Lithothamnion 
corallioides which is rich in calcium, magnesium and minerals, such as manganese, 
selenium and zinc [109]. Given that a previously published clinical trial using this compound 
showed improvements in the OA symptoms, Frestedt et al. performed a small preliminary 
randomised, double-blind, placebo controlled pilot study to investigate the potential of 
Aquamin® to reduce the NSAID usage in subjects with moderate to severe knee OA [109]. 
The results demonstrated that Aquamin® increases the individuals range of motion and 
walking distances, and allows the partial withdrawal of NSAIDs in subjects with OA, 
although cannot entirely replace NSAIDs as a treatment for OA [109]. These data suggest 
that Aquamin® may allow a reduced need for NSAIDs usage in the management of OA 
symptoms [109]. Maritech® is a seaweed extract formulation rich in fucoidan, a class of 
sulfated fucose-rich polysaccharides that have been shown to have a range of anti-
inflammatory effects [110]. This formulation contains a blend of extracts from three brown 
algae species (Fucus vesiculosis, Macrocystis pyrifera, Laminaria japonica.) plus vitamin 
B6, zinc and manganese [110]. It was tested in an open label combined phase I and II pilot 
scale study to determine both safety and efficacy in the treatment of knee OA [110]. The 
results demonstrated that Maritech® is safe and efficient in reducing OA symptoms, which 
suggests its potential benefit in the treatment of this disease [110].  
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These and other natural compounds appears to be capable of treating OA clinically, 
since they contribute to alleviate OA symptoms and joint function and cause few or no 
undesirable side effects. The features of these natural compounds can enable the reduction 
of the use of conventional drug therapy, and makes them good alternative in the treatment 
of OA, mainly in patients who require long-term treatment.  
 
1.3.1.2 Natural compounds with OA-modifying effect 
 
 
Several natural compounds also have shown promising results as disease-modifying 
OA drugs (DMOADs) able to prevent, slow or stop the OA pathophysiological events.  
 Some of the compounds described above which had effects on the symptomatic OA 
treatment also showed disease-modifying effects.     
The effects of the glucosamine sulphate on the long-term progression of OA joint 
structure changes was assessed, in a randomized, double-blind, placebo controlled clinical 
trial, in patients with OA knee [111]. Glucosamine sulphate prevented significant joint-space 
narrowing in the patients with knee OA, which suggests that this compound might have 
structure-modifying effects [111]. Another clinical trial conducted under similar conditions 
tested the structure-modifying and symptom-modifying effects of chondroitin sulphate, and 
concluded that this compound significantly prevented the joint-space narrowing in patients 
with knee OA [88]. These results indicate that glucosamine sulphate and chondroitin 
sulphate had great potential as DMOADs and therefore represented a promising 
therapeutic alternative for OA patients.   
Avocado/soybean unsaponifiables (ASU) also showed a protective effect on OA 
structural changes, when tested using an experimental OA dog model [112]. This treatment 
with ASU reduced the development of early OA cartilage and significantly decreased 
mediators of cartilage matrix damage, as well as chondrocyte hyperplasia and cloning [112]. 
Moreover, OA subchondral bone lesions were also reduced and it was able to maintain 
subchondral bone and calcified cartilage structure close to normal values [112]. Together 
these results suggest the use of ASU as DMOAD. 
Boswellic acid, a molecule derived from the plant Boswellia serrata, is another 
potential DMOAD that attenuates joint damage in OA, as observed using an established 
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OA mouse model where there was reduction of cartilage loss, synovitis and osteophyte 
formation [113]. 
Resveratrol (3,5,4-trihydroxystilbene) is a natural phytoalexin (polyphenolic 
compound) found in the skin of red grapes, cranberries, peanuts, and root extracts of the 
weed Polygonum cuspidatum, which has anti-inflammatory, anti-carcinogen, anti-aging, 
and antioxidant properties [114]. In an experimental OA rabbit model, the effect of 
Resveratrol on cartilage, chondrocyte apoptosis, and nitric oxide levels was assessed, and 
the results revealed that this natural compound significantly reduced cartilage destruction, 
loss of matrix proteoglycan content, apoptosis rate of chondrocyte and level of NO in the 
synovial fluid, showing its cartilage protective effect in the experimental OA model and 
suggesting its potential as DMOAD [114].  
  
These and other natural compounds appears to be able of slowing the deterioration 
of cartilage and OA progression, which makes them a good therapy to control or even 
prevent the progression of the disease to terminal stages and thus, improve the quality of 
life of the patients and reduce the need for surgical joint replacement interventions. 
 
 
1.3.1.3 Emerging natural compounds for the OA treatment 
 
Several natural compounds, currently in pre-clinical research, have shown anti-
inflammatory activity in in vitro OA study models, which suggests its therapeutic potential 
for the treatment of this disease.  
In 2014, Ying et al. evaluated the role of Cordycepin, a nucleoside derivative 
isolated from the fungus Cordyceps, in the inflammatory response of IL-1β-stimulated 
human OA chondrocytes [115]. They found that this compound prevented PGE2, NO, 
MMP-13, IL-6 and COX-2 production by these stimulated cells [115]. Also Wang et al. and 
Jingbo et al., in 2015, investigated the anti-inflammatory effects, respectively, of 
Diosgenin [116], a steroidal saponin found in plants such as Solanum and Dioscorea species, 
and Betulinic acid (BA) [117], a triterpenoid isolated from birch bark, using the same in 
vitro OA model. The results showed that Diogenin inhibited the production of NO and 
PGE2, as well as the expression of MMP-3, MMP-13, iNOS and COX-2 in human OA 
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chondrocytes [116], and BA dose-dependently inhibited MMP-1, MMP-3, MMP-13, PGE2 
and NO productions in the same cell type [117]. The results indicated that the three natural 
compounds had anti-inflammatory effects in OA, and further suggest that they can be 
potential therapeutic drugs in the OA treatment. 
Astaxanthin, a red carotenoid pigment that can be found in various marine plants 
and animals, such as shrimps and salmon, possesses multiple biological functions, 
including anti-inflammatory activity [118]. Chen et al. investigated the effects of 
Astaxanthin on cartilage protection, evaluating its effects on the expression of MMPs in 
human OA chondrocytes [118]. The results showed that Astaxanthin significantly inhibits 
MMP-1, MMP-3 and MMP-13 in IL-1β-induced chondrocytes, which suggests that this 
compound may have beneficial effects in the OA treatment [118].  
A co-culture model using human OA chondrocytes in alginate beads and non-
sclerotic or sclerotic subchondral osteoblasts in monolayer, showed the anti-inflammatory 
and anti-catabolic effects of Carnosol, a rosemary-derived polyphenol, in OA [119]. The 
results demonstrated that Carnosol exerts a protective effect on the deleterious activities of 
OA subchondral osteoblasts on chondrocytes, since OA sclerotic subchondral osteoblasts 
treated with this compound mediate an increase in cartilage matrix formation components 
(aggrecan, type II collagen) and a decrease in gene expression of matrix degradation 
enzymes (MMP-3, ADAMTS-4 and ADAMTS-5) in chondrocytes [119]. Thus, Carnosol 
seems to have a potent anti-inflammatory and anti-catabolic effect of cartilage breakdown 
in chondrocytes, indicating its potential as a therapeutic drug for the OA treatment [119]. 
 
Although these natural compounds have revealed therapeutic potential for the OA 
treatment in in vitro studies, in vivo studies and clinical trials need to be performed to 
demonstrate its therapeutic efficacy in this disease. 
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1.4 Bioactive compounds from the brown algae Cystoseira 
usneoides  
 
Brown algae of the genus Cystoseira comprises about 50 species worldwide 
distributed through subtropical waters, with the biggest species diversity and abundance 
found in the Mediterranean Sea and along the Northeastern Atlantic coasts [120, 121]. 
Cystoseira algae are a prolific source of meroditerpenoids, secondary metabolites 
of mixed biogenesis, whose structures are formed by a toluquinol nucleus linked to a 
diterpenoid moiety [120, 121]. The diterpenoid portion of the compounds can have great 
structural diversity, including linear, cyclic, regular, and rearranged frameworks [121]. 
 
 
 
 
 
 
Figure 1.7 Generic chemical structure of meroditerpenoids isolated from the Cystoseira algae. The 
chemical structure of the meroditerpenoids is formed by a toluquinol nucleus linked to a diterpenoid moiety 
which can be linear, cyclic, regular, and rearranged frameworks. Adapted from [120]. 
 
Meroditerpenoids from the Cystoseira algae have been described to have cytotoxic, 
antibacterial, antiviral and antioxidant properties [120, 121]. However, recent reports of new 
metabolites produced by Cystoseira have included other types of bioactivities, such as anti-
inflammatory properties, which creates new opportunities for research and potential 
applications of the meroditerpenoids of these brown algae [120]. 
Recently, de los Reyes et al. isolated twelve new meroditerpenoids along with eight 
known compounds from Cystoseira usneoides, a brown algae specie of the genus 
Cystoseira, collected at the coast of Tarifa (Spain) [120].  
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Figure 1.8 Brown algae Cystoseira usneoides. Brown algae specie of the genus Cystoseira mostly found in 
the Mediterranean Sea and along the Northeastern Atlantic coasts. Adapted from [122]. 
 
Samples of Cystoseira usneoides were first extracted with methanol then with 
diethyl ether followed by a series of separation by column chromatography and final 
purification by normal-phase and reversed-phase high performance liquid chromatography 
(HPLC) [120]. The structures determination of the pure compounds has been established by 
spectroscopic techniques [120]. Among the isolated natural products, five of them, identified 
as meroditerpenoids (cystodione G, cystodione M, cystone C, 11-hydroxyamentadione and 
amentadione) (Table 1.4), showed a significant in vitro anti-inflammatory activity [120]. To 
study anti-inflammatory activity of these compounds, they tested their activity as inhibitors 
of the pro-inflammatory cytokine TNF-α [120]. As a result, all five compounds showed a 
significant activity as inhibitors of the production of the pro-inflammatory cytokine TNF-α 
in lipopolysaccharide (LPS)-stimulated THP-1 macrophages [120]. 
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Table 1.4 Chemical information of bioactive compounds with anti-inflammatory 
activity isolated from the brown algae Cystoseira usneoides [120].   
    
Name of 
compound 
Molecula
r formula 
Chemical structure 
Amentadione C27H38O5 
 
11-
Hydroxyamentadi
one 
C27H38O6 
 
 
Cystodione G C27H38O6 
 
Cystodione M C28H40O7 
 
Cystone C C28H42O5 
 
 
 
These findings clearly suggested that these marine bioactive compounds could be 
useful in the therapeutics of inflammatory-related diseases and leaded us to further explore 
their potential as novel therapeutic agents for OA. 
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II. Objectives  
 
 
OA is the most frequent chronic musculoskeletal disorder, and the leading cause of 
pain and disability in the elderly. Currently, this disease has no cure and the therapeutic 
strategies are limited to drugs which only control and relieve the symptoms, without being 
able prevent, reduce or stop the OA progression, in addition to, in some cases, causing 
undesirable side-effects. The natural products are potential sources of new pharmaceutical 
compounds for the OA treatment, since they have proven to be safe and have therapeutic 
effects in this disease. Recent data indicating the anti-inflammatory activity of several 
meroditerpenoids isolated from the alga Cystoseira usneoides suggest its potential as 
therapeutics of the inflammatory-related diseases. For these reasons, an objective of this 
thesis is to explore the potential of three of these meroditerpenoids as novel therapeutic 
agents for OA, using in vitro OA models, such as monolayer human articular primary cells 
culture and a co-culture system of healthy articular cartilage explants and primary 
synoviocytes exposed to inflammatory OA conditions.     
 It is also our objective to begin to develop and optimize a 3D in vitro/ex vivo OA-
model that recreates the human articular system and enables a closer-to-in vivo study of 
human OA disease. The success of this objective will enable us, in a near future, use this 
model to study the OA condition and to confirm the therapeutic effect of the bioactive 
marine compounds previously selected in the in vitro human articular primary culture 
system, and validate them as new drugs for OA treatment. 
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III. Materials and Methods 
 
3.1   Cell Culture 
 
3.1.1 THP-1 cells culture and differentiation 
 
Human monocytic leukemia cell line THP-1 was cultured in RPMI 1640 with L-
Glutamine (Lonza) supplemented with 10% (v/v) of heat-inactivated fetal bovine serum 
(FBS) (Sigma-Aldrich) and 1% (v/v) of penicillin-streptomycin (Invitrogen), at 37°C in a 
humidified atmosphere containing 5% CO2. For differentiation into human macrophages 
(THP-1 MoM), THP-1 cells (1.25 × 106 cells/ml) were cultured in complete RPMI 
supplemented with 25 ng/ml of Phorbol Myristate Acetate (PMA) (Sigma-Aldrich) for 48 
hours, at 37°C in a humidified atmosphere containing 5% CO2. All experiments were 
performed on confluent cells.  
 
3.1.2 Chondrocytes and Synoviocytes culture 
 
Human normal chondrocytes (NC) and human fibroblast-like synoviocytes (HFLS) 
[6] were cultured in advanced Dulbecco’s Modified Eagle’s Medium (DMEM) (Invitrogen) 
supplemented with 10% (v/v) of heat-inactivated FBS (Sigma-Aldrich), 1 mM of L-
Glutamine (Invitrogen) and 1% (v/v) of penicillin-streptomycin (Invitrogen), at 37°C in a 
humidified atmosphere containing 5% CO2. All experiments were performed on confluent 
cells between passages 10 and 19. 
 
3.1.3 Articular cartilage collection, processing and explant culture 
  
Articular cartilage samples were obtained from patients undergoing total knee 
replacement surgery (using bone and cartilage obtained from bone cuts) performed at the 
Orthopedics Department of Algarve Medical Centre (in collaboration with members from 
the surgical staff). This study complies with the guidelines for good clinical practice and 
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was performed in accordance with the Declaration of Helsinki and approved by the Ethics 
Committee of the Algarve Medical Center. Written informed consent was obtained from 
all participants. Normal full-depth cartilage slices, without any signs of degeneration, were 
selected based on the macroscopic evaluation of the members of the surgical staff. The 
samples were removed in sterile conditions and collected in advanced DMEM (Invitrogen) 
supplemented with 10% (v/v) of heat-inactivated FBS (Sigma-Aldrich), 1 mM of L-
Glutamine (Invitrogen) and 1% (v/v) of penicillin-streptomycin (Invitrogen). For tissue 
equilibration before preparation of tissue explants, samples were incubated for 24 hours, at 
37ºC in a humidified atmosphere containing 5% CO2. After 24 hours equilibration, 2 mm 
diameter cartilage explant disks were obtained using a 2 mm biopsy punch (Miltex), and 
immediately used in the experiments. 
 
3.1.4 Co-culture of synoviocytes and articular cartilage explants   
 
To establish a co-culture system of HFLS and healthy articular cartilage explants, a 
transwell permeable support was used. Confluent HFLS cultured as described in 3.1.2 were 
plated in 6.5 mm diameter transwell inserts (Corning) with a 3.0 µm pored polyester 
membrane. These cells remain under these conditions overnight, at 37ºC in a humidified 
atmosphere containing 5% CO2, to adhere. A minimum of five cartilage explants processed 
as described in 3.1.3 were then placed on the bottom of each well of a 24-well plate, and 
transwell inserts with stabilized HLFS monolayer were placed upon the cartilage explants. 
This co-culture was immediately used in the experiments.  
 
3.2   Cell viability assay 
 
The effect of three marine compounds (Amentadione (YP), Cystodione G (Cyd G) 
and 11-Hydroxyamentadione (Cyd K)) and of a dispersion of HAP nanoparticles (< 200 
nm) (10 wt. % of HAP in H2O) (Sigma-Aldrich) on cell viability of THP-1 MoM, NC and 
HFLS was assessed using CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay 
(Promega). This colorimetric method determines the number of viable cells in culture. It is 
composed by a solution of a novel tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and an 
41 
 
 
electron coupling reagent (phenazine methosulfate; PMS). In this assay, MTS is reduced 
by the cells into a formazan product which is soluble in tissue culture medium and the 
absorbance is measured at 490 nm. The number of living cells in culture is assessed by the 
quantity of formazan product which is directly proportional to the absorbance measured at 
490 nm. To evaluate the effect of marine compounds and HAP nanoparticles on cell 
viability, THP-1 MoM cells were seeded in 96-well plates at 2.5×105 cells/well, and NC 
and HFLS were seeded in 96-well plates at 2×104 cells/well. Cells were cultured with their 
respective growth medium, alone or supplemented with 2.5 µM, 5 µM or 10 µM of marine 
compounds for 24 hours, or 250 µg/ml and 500 µg/ml of HAP nanoparticles for 72 hours, 
at 37ºC in a humidified atmosphere containing 5% CO2. Then, following the kit 
manufacturer's instructions, the cells were incubated with combined MTS/PMS solution 
for 1 hour, at 37ºC in a humidified atmosphere containing 5% CO2. Cell viability was 
analysed by measuring the absorbance at 490 nm on a microplate reader Synergy4 
(Biotek). The culture medium was used as a blank.  
 
3.3   Inflammatory assays       
  
Confluent THP-1 MoM were cultured in complete RPMI alone or supplemented 
with 250 µg/ml and 500 µg/ml of HAP nanoparticles (Sigma-Aldrich), or 100 ng/ml of 
lipopolysaccharide (LPS) from Escherichia coli 0111: B4 (Sigma-Aldrich), for 72 hours, at 
37°C in a humidified atmosphere containing 5% CO2. At the end, the culture medium was 
collected, centrifuged to separate cell debris and stored at -80ºC until further analysis.  
Articular cartilage explants were cultured in complete advanced DMEM alone or 
supplemented with 10 ng/ml of IL-1β for 24, 48 or 72 hours, at 37°C in a humidified 
atmosphere containing 5% CO2. At the various experimental time points, the cartilage 
explants were collected and immediately processed for RNA extraction. 
Co-culture system of HFLS and articular cartilage explants was cultured in 
complete advanced DMEM alone or supplemented with 10 ng/ml and 100 ng/ml of IL-1β 
for 1 week, at 37°C in a humidified atmosphere containing 5% CO2. Culture media was 
renewed twice a week with fresh medium. At the end, the cartilage explants were collected 
and immediately processed for histological analysis.  
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3.4   Anti-inflammatory activity of marine compounds  
      
Confluent THP-1 MoM were cultured in complete RPMI alone or supplemented 
with 10 µM of marine compounds (YP, Cyd G or Cyd K) or 2 µM of dexamethasone 
(Dex) (Sigma-Aldrich) as positive control, for 2 hours at 37°C in a humidified atmosphere 
containing 5% CO2. After, 100 ng/ml of LPS (Sigma-Aldrich) or 250 µg/ml of HAP 
nanoparticles (Sigma-Aldrich) were added to culture medium for another 24 or 72 hours, 
respectively, under the same culture conditions. At the end, the culture medium was 
collected, centrifuged to separate cell debris and stored at -80ºC until further analysis.  
Confluent NC and HFLS were cultured in complete advanced DMEM alone or 
supplemented with 10 µM of marine compound YP for 24 hours, at 37°C in a humidified 
atmosphere containing 5% CO2. After, 10 ng/ml of IL-1β were added to culture medium 
for another 3, 6 or 11 hours, under the same culture conditions. Cells at the various 
experimental time points were collected and stored at -80ºC for RNA extraction. 
Co-culture system of HFLS and articular cartilage explants was cultured in 
complete advanced DMEM alone or supplemented with 10 ng/ml of IL-1β or 10 µM of 
marine compound YP and 10 ng/ml of IL-1β for 1 week, at 37°C in a humidified 
atmosphere containing 5% CO2. Culture media was renewed twice a week with fresh 
medium. At the end, the cartilage explants were collected and immediately processed for 
histological analysis.  
 
3.5   Mineralization assay 
 
Articular cartilage explants were cultured in complete advanced DMEM alone or 
supplemented with calcium (Ca) and phosphate (P) (5.4 mM calcium chloride (CaCl2) + 
2.5 mM potassium dihydrogen phosphate (KH2PO4)) or with Ca only (5.4 mM CaCl2). The 
cartilage explants culture was maintained for 3 weeks, at 37°C in a humidified atmosphere 
containing 5% CO2. Culture media was renewed twice a week with fresh medium. At the 
end, the cartilage explants were collected and immediately processed for Ca2+ 
quantification and histological analysis. 
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3.6   TNF-α Enzyme-linked immunosorbent assay  
 
The effect of marine compounds (YP, Cyd G and Cyd K) and of HAP nanoparticles 
on the level of TNF-α secreted in culture medium by THP-1 MoM was assessed using a 
human TNF-α ELISA kit (Peprotech) and following the manufacture’s protocol. This 
sandwich ELISA allows the quantitative measurement of natural and/or recombinant 
human TNF-α within the range of 16-2000 pg/ml. In brief, a first antibody, called capture 
antibody, was used to coat the plate wells. After, the non-specific binding sites on the 
surface were blocked using a blocking buffer. Samples were added on the plate and the 
capture antibody immobilized the antigen of interest. Then, a second antibody, the 
detection antibody, was used to bind the captured antigen and enable subsequent detection. 
Avidin-horseradish peroxidase conjugate was added, and bound to the immobilized 
antibody-antigen complex. Any unbound reagents were removed by performing several 
washing steps. Lastly, ABTS substrate was added and colour development was measured 
at 405 nm with a wavelength correction set to 650 nm, on a microplate reader Synergy4 
(Biotek). The concentration of TNF-α was determined by comparison with a standard 
curve prepared using known TNF-α concentrations. The culture medium was used as a 
blank. 
 
3.7   RNA extraction and quantification    
   
Total RNA from articular cartilage tissue explants, NC and HFLS cultures was 
isolated following the protocol described by Chomczynski and Sacchi [123], although with 
some adjustments (Appendice I). Nucleic acids strongly absorb light in the ultraviolet 
(UV) region of the spectrum, and UV spectrophotometry is a traditional approach to 
assessing the concentration of RNA. The reading at 260 nm allows calculation of the 
nucleic acid concentration in the sample. RNA concentration was quantified by the UV 
spectrophotometry, by measuring the absorbance at 260 nm on a spectrophotometer 
Nanodrop1000 (Thermo Scientific). In this method, the RNA concentration is calculated 
using the Beer-Lambert law, and based on the assumption that 1 absorbance unit at 260 nm 
correspond to 40 µg/ml of single-stranded RNA [124].      
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3.8   cDNA synthesis by Reverse Transcription reaction 
 
Complementary DNA (cDNA) was synthesized by reverse transcription of RNA, 
using a thermocycler (Applied Biosystems). Total RNA was treated with RQ1 RNase-Free 
DNase, to degrade both double-stranded and single-stranded DNA. Reaction was 
performed using 1 unit of RQ1 RNase-Free DNase (Promega) and 1X of RQ1 RNase-Free 
DNase 10X Reaction Buffer (Promega), at 37°C for 30 minutes and at 65ºC for 10 
minutes. Then, total RNA was reverse transcribed using 1X of qScriptTM cDNA 
SuperMix (Quanta BioSciences), according to the manufacturer’s instructions. Reaction 
was performed at 25ºC for 5 minutes, 42ºC for 30 minutes and 85ºC for 5 minutes. 
Synthesized cDNA was stored at -20ºC until further use. 
 
3.9   Quantitative Real-Time Polymerase Chain Reaction 
(RT-qPCR) 
 
cDNA was amplified by quantitative real-time polymerase chain reaction (RT-
qPCR), a method that allows determining the starting template copy number with accuracy 
and high sensitivity [125]. This method uses a fluorescent molecule and the increase in the 
amount of amplified product in each cycle will lead to a proportional increase in 
fluorescent signal [125].  Its makes the continuous collection of fluorescent signal from one 
or more polymerase chain reactions over a range of cycles, and converts the fluorescent 
signals from each reaction into a numerical value for each sample [125].   
 Reaction was performed in an iCycler iQ apparatus (Bio-Rad), using 1X of SsoFast 
Eva Green Supermix (Bio-Rad), 0.3µM of forward and reverse gene-specific primers for 
genes of interest (Table 3.1), and 1:5 dilution of cDNA. RT-qPCR conditions used were 
initial denaturation/enzyme activation step at 95ºC for 13 minutes and 60 cycles of 
amplification (one cycle is 15 seconds at 95ºC and 30 seconds at 68ºC). Fluorescence was 
measured at the end of each extension cycle in the FAM-490 channel. Levels of gene 
expression were calculated using the comparative ∆∆Ct method, and normalized using 
gene expression levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
housekeeping gene, with the iQ5 software (BioRad).  
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Table 3.1 Primer sequences used in RT-qPCRs  
 
Gene Sense Primer sequence (5’ – 3’) 
GAPDH 
Forward 
AAG GTG AAG GTC GGA 
GTC AAC GGA 
Reverse 
TCG CTC CTG GAA GAT 
GGT GAT GGG 
Human NF-kB 
Forward 
GCA ATC ATC CAC CTT 
CAT TCT CAA CTT 
Reverse 
CCT CCA CCA CAT CTT 
CCT GCT TAG 
Human COX-2 
Forward 
TGG TCT GGT GCC TGG 
TCT GAT GAT GT 
Reverse 
GCC TGC TTG TCT GGA 
ACA ACT GCT CA 
Human MMP-13 
Forward 
AAC CGT ATT GTT CGC 
GTC ATG CCA G 
Reverse 
GAT AGC TCT TCT TCC 
CCT ACC CCG C 
 
 
3.10 Calcium quantification 
 
Articular cartilage explants subjected to mineralization assay were minced on liquid 
nitrogen and reduced to a fine powder, lyophilized, weighed and then completely digested 
overnight with 100 µl of 68% nitric acid (HNO3) (VWR) per each 1-2 mg of tissue, at room 
temperature with agitation. Then, the calcium content in the acid-digested explants solution 
was determined using a colorimetric calcium assay CA-590 (Randox) following the 
manufacturer's protocol. The absorbance of the chromogenic complex formed between 
calcium ions and O-Cresolphthalein complexone is measured by spectrophotometry at 570 
nm, using a microplate reader Synergy4 (Biotek). The calcium content was determined by 
comparison with a calibration curve performed at the same time, with standards of known 
calcium concentration, and normalized to the cartilage explants dry weight. A 10% 
solution of HNO3 was used as a blank. 
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3.11 Tissue histological characterization  
 
For tissue histological analysis, articular cartilage explants immediately after 
undergoing the assays were collected in sterile 4% w/v paraformaldehyde (PFA) solution. 
After fixation in PFA, the tissue samples were embedded in paraffin, 7 µm tissue cuts were 
performed, and slides were assembled and stained with haematoxylin-eosin staining, by the 
Pathology Department of the Algarve Medical Centre using standard procedures. Before 
the staining procedures, slides were dewaxed in xylene, rehydrated through an ethanol 
series, and washed in water as follows: 10 minutes in xylene (step run 2 times); 6 minutes 
in 100% ethanol; 6 minutes in 70% ethanol; 6 minutes in 50% ethanol; and 5 minutes in 
bidistilled water (step run 2 times). Mineral content was detected by the von Kossa 
method. After paraffin removal and hydration, slides were incubated with 1% silver nitrate 
(Sigma-Aldrich) under UV light until the tissue is stained, washed with bidistilled water, 
counterstained with haematoxylin (Klinipath) for 3 minutes, and immersed in tap water for 
10 minutes. Glycosaminoglycan content was detected using the Alcian Blue stain kit (pH 
2.5) (Atom Scientific), following the manufacture’s protocol. After paraffin removal and 
hydration, slides were stained with 1% alcian blue for 30 minutes, rinsed with 3% acetic 
acid for 10-20 seconds, washed in running tap water for 5 minutes, counterstained with 
0,5% neutral red for 5 minutes, and rinsed quickly in bidistilled water. Images were 
obtained at the Light Microscopy Unit of the Department of Medicine and Biomedical 
Sciences, UAlg. 
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IV. Results 
 
4.1   Marine compounds Amentadione, Cystodione G and 11-
Hydroxyamentadione do not affect cell viability of 
macrophages, chondrocytes and synoviocytes 
 
The cytotoxic effect of the marine compound amentadione (YP) was determined in 
previous studies performed by our research group, and the results showed that 2.5 µM, 5 
µM and 10 µM of the compound is non-cytotoxic in THP-1 macrophages and primary 
cultures of human chondrocytes and synoviocytes (unpublished).    
 To evaluate the cytotoxic effect of the marine compounds cystodione G (Cyd G) 
and 11-hydroxyamentadione (Cyd K) in THP-1 macrophages, chondrocytes and 
synoviocytes, a cell viability assay was performed after treating the cells with each 
compound for 24 hours. As shown in Figure 4.1, Cyd G and Cyd K in concentrations 
ranging between 2.5 µM and 10 µM do not affect cell viability of THP-1 macrophages (a), 
chondrocytes (b) and synoviocytes (c), when compared to the respective untreated cells 
used as control.  
 
 
 
Figure 4.1 Effect of Cyd G and Cyd K on cell viability of macrophages, chondrocytes and synoviocytes. 
Cell viability of a) THP-1 macrophages (THP-1 MoM), b) chondrocytes (CN primary cell line) and c) 
synoviocytes (HFLS primary cell line) incubated with compounds Cyd G and Cyd K (2.5µM, 5 µM and 10 
µM) for 24h was assessed using CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay. Control 
(CTR) corresponds to untreated cells. All experiments were performed in duplicate. Data are presented as 
means ± standard deviation. 
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4.2   Marine compounds Amentadione, Cystodione G and 11-
Hydroxyamentadione reduce TNF-α production in LPS 
and HAP-stimulated macrophages 
 
The effect of marine compounds amentadione (YP), cystodione G (Cyd G) and 11-
hydroxyamentadione (Cyd K) on the inflammatory reaction of macrophages when 
stimulated with LPS or HAP was determined by measuring the production of the pro-
inflammatory agent TNF-α.          
 Before testing the effect of the compounds, the cytotoxic effect of HAP crystals in 
THP-1 macrophages was evaluated by treating the cells with 250 µg/ml and 500 µg/ml of 
HAP nanoparticles during 72 hours. Figure 4.2a shows that HAP concentrations of 250 
µg/ml and 500 µg/ml do not affect cell viability of THP-1 macrophages, when compared to 
the untreated cells used as control. To further evaluate whether the HAP crystals were able 
to induce an inflammatory response in THP-1 macrophages, the levels of TNF-α 
production were determined after stimulation for 72 hours with HAP (250 µg/ml and 500 
µg/ml). The results showed that both doses of HAP significantly increased TNF-α 
production, when compared to control samples (untreated cells) (Figure 4.2b). Of note, 250 
µg/ml HAP concentration practically equalled the levels of TNF-α production in LPS-
stimulated THP-1 macrophages, used as positive control for the inflammatory reaction.  
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Figure 4.2 Effect of HAP crystals on cell viability and TNF-α production in macrophages. a) Cell 
viability of THP-1 macrophages (THP-1 MoM) incubated with HAP nanoparticles (250 µg/ml and 500 
µg/ml) for 72h was assessed using CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay. Control 
(CTR) corresponds to untreated cells. Experiment was performed in duplicate. Data are presented as means ± 
standard deviation. b) TNF-α in supernatants of THP-1 macrophages (THP-1 MoM) treated as described in 
(a) was quantified by ELISA. Stimulation with LPS (100 ng/ml) was performed for comparison. Control 
(CTR) corresponds to culture media of untreated cells. Experiment was performed in duplicate. One-way 
ANOVA was performed. Statistical significance was defined as p ≤ 0,01 (**). 
     
The effect of marine compounds YP, Cyd G and Cyd K in the inflammatory 
response of THP-1 macrophages stimulated with HAP and LPS was then evaluated by 
measuring the levels of TNF-α production. In this assay, the 250 µg/ml HAP concentration 
was chosen, since it corresponded to a greater increase in the TNF-α production in THP-1 
macrophages (Figure 4.2b). The cells were pre-treated with YP, Cyd G, Cyd K or Dex 
(used as a control anti-inflammatory agent) for 2 hours and then stimulated with LPS for 
24 hours, or HAP nanoparticles for 72 hours. TNF-α was quantified by ELISA in the cell 
supernatants. Figure 4.3a shows that the stimulation of THP-1 macrophages with LPS 
significantly increased the production of TNF-α compared to control samples (untreated 
cells), that the treatment with YP, Cyd G and Cyd K significantly inhibited the production 
of TNF-α in these cells, and that the three marine compounds induced a greater inhibition 
than Dex. Figure 4.3b shows that stimulation of THP-1 macrophages with HAP also 
significantly increased the production of TNF-α compared to control samples (untreated 
cells), and that the treatment with the three marine compounds inhibited the production of 
TNF-α in these cells, although in this case, the greater inhibition of TNF-α production is 
observed in cells treated with the marine compound Cyd K. In HAP-stimulated THP-1 
macrophages, pre-treatment with Dex increased the production of TNF-α, contrary to the 
results observed in LPS-stimulated THP-1 macrophages. 
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Figure 4.3 Effect of YP, Cyd G and Cyd K on LPS and HAP-induced TNF-α production in 
macrophages. TNF- was quantified by ELISA in supernatants of THP-1 macrophages (THP-1 MoM) pre-
treated with compounds YP, Cyd G and Cyd K (10 µM) or Dex (2 µM) for 2h and then stimulated with LPS 
(100 ng/ml) for 24h (a) or HAP (250 µg/ml) for 72h (b). Control (CTR) corresponds to culture media of 
untreated cells. Both experiments were performed in duplicate. One-way ANOVA was performed. Statistical 
significance was defined as p ≤ 0,05 (*), p ≤ 0,01 (**), p ≤ 0,001 (***) and p ≤ 0,0001 (****).  
 
 
4.3   Marine compound Amentadione reduces gene 
expression of OA-related inflammation markers in IL-1β-
stimulated chondrocytes and synoviocytes    
    
Although the results obtained with all marine compounds tested in the THP-1 cell 
cultures have shown an anti-inflammatory effect by decreasing the production of TNF-α, 
only the compound amentadione (YP) was selected for further testing in the articular 
human cell system (primary cultures of chondrocytes and synoviocytes).    
 To evaluate the anti-inflammatory potential of YP in the chondrocyte and 
synoviocyte articular cell system, cells were stimulated with IL-1β using previously 
described conditions [117, 118, 126], and levels of COX-2 and NF-kB gene expression were 
determined by RT-qPCR. Cells were pre-treated with YP for 24 hours and then stimulated 
with IL-1β for 3, 6 or 11 hours. The results showed that stimulation of chondrocytes with 
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IL-1β significantly induced the COX-2 (Figure 4.4a) and NF-kB (Figure 4.4b) gene 
expression compared to control samples (untreated cells), with an expression peak at 6 
hours post-stimulation. The treatment with YP strongly reduced COX-2 gene expression at 
3 and 6 hours after inflammation with IL-1β (Figure 4.4a), as well as NF-kB gene 
expression at 3, 6 and 11 hours after IL-1β stimulation (Figure 4.4b). At 11 hours, YP 
shows no effect in the reduction of COX-2 gene expression (Figure 4.4a).  
 
 
Figure 4.4 Effect of YP on IL-1β-induced COX-2 and NF-kB gene expression in chondrocytes. COX-2 
a) and NF-kB b) expression levels in chondrocytes (CN primary cell line) pre-treated with YP (10 µM) for 
24h and then stimulated with IL-1β (10 ng/ml) for 3h, 6h and 11h were quantitatively determined by RT-
qPCR. Control (CTR) corresponds to untreated cells. Experiment was performed in duplicate. One-way 
ANOVA was performed. Statistical significance was defined as p ≤ 0,05 (*) and p ≤ 0,01 (**). 
 
In synoviocytes (Figure 4.5), the stimulation with IL-1β also significantly induces 
the COX-2 gene expression compared to control samples (untreated cells), but only at 6 
hours post-stimulation. At this time point, the treatment with YP strongly reduces COX-2 
gene expression induced by IL-1β stimulation. We did not obtain results regarding the NF-
kB gene expression in these cells due to constrains on the amount of RNA available for 
gene amplification.  
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Figure 4.5 Effect of YP on IL-1β-induced COX-2 gene expression in synoviocytes. COX-2 expression 
levels in synoviocytes (HFLS primary cell line) pre-treated with YP (10 µM) for 24h and then stimulated 
with IL-1β (10 ng/ml) for 3h, 6h and 11h were quantitatively determined by RT-qPCR. Control (CTR) 
corresponds to untreated cells. Experiment was performed in duplicate. One-way ANOVA was performed. 
Statistical significance was defined as p ≤ 0,001 (***). 
 
 
4.4   In vitro healthy articular cartilage explants have 
inflammation and mineralization capacity 
 
As a preliminary study for the establishment of the 3D in vitro/ex vivo model to 
study the OA condition, we characterized the in vitro healthy articular cartilage explants 
system in both inflammatory and mineralization conditions.    
 To test the inflammatory capacity of in vitro cartilage explants, we used 
inflammatory conditions previously described for an explant model of articular cartilage 
[21]. 2 mm diameter healthy cartilage disks were stimulated with IL-1β for 24, 48 or 72 
hours, and gene expression of selected OA-related markers (COX-2, MMP-13 and NF-kB) 
were quantitatively determined by RT-qPCR, in the three experimental time points. Results 
shows that stimulation of cartilage explants with IL-1β induce the COX-2 (Figure 4.6a), 
MMP-13 (Figure 4.6b) and NF-kB (Figure 4.6c) gene expression compared to control 
samples (untreated cartilage explants), at 24, 48 and 72 hours. While COX-2 and MMP-13 
gene expression was upregulated 24 hours after stimulation, when compared with control, 
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upregulation of NF-kB is only evident after 48 hours. Taken together, these results indicate 
that healthy cartilage explants have inflammatory capacity in vitro. 
 
 
Figure 4.6 Inflammation capacity of the in vitro healthy articular cartilage explants. COX-2 a), MMP-
13 b) and NF-kB c) expression levels in cartilage explants stimulated with IL-1β (10 ng/ml) for 24h, 48h or 
72h were quantitatively determined by RT-qPCR. Control (CTR) corresponds to untreated cartilage explants. 
Experiment was performed only once. 
 
To analyse the mineralization capacity of the in vitro cartilage explants, we used 
mineralizing conditions previously described for monolayer articular cultures [6] and aortic 
segments [127]. 2 mm diameter healthy cartilage disks were treated with Ca and Ca + P for 3 
weeks, and mineralization was assessed by total calcium quantification using a 
colorimetric method and also histologically, in tissue sections, by the von Kossa staining 
procedure. Calcium quantification (Figure 4.7) shows that both mineralizing conditions 
tested (Ca or Ca + P) were able to induce mineralization of cartilage explants when 
compared to control samples (untreated cartilage explants), although stimulation with Ca 
induced higher levels of mineral deposition in cartilage explants when compared with Ca + 
P treatment.  
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Figure 4.7 Mineralization capacity of the in vitro healthy cartilage explants assessed by calcium 
quantification. Mineralization of in vitro cartilage explants stimulated with a final concentration of 5.4 mM 
CaCl2 (Ca) + 2.5 mM KH2PO4 (P) or 5.4 mM CaCl2 (Ca) for 3 weeks was assessed by calcium quantification 
using the colorimetric assay CA-590. Control (CTR) corresponds to untreated cartilage explants. Experiment 
was performed in duplicate. One-way ANOVA was performed. Statistical significance was defined as p ≤ 
0,01 (**) and as p ≤ 0,001 (***). 
 
The histological analysis of tissue sections using the von Kossa staining also 
confirmed the results obtained by calcium quantification. Untreated cartilage explants 
(CTR) exhibit histological features of a healthy cartilage tissue, showing a thin superficial 
zone (SZ) containing small and flat chondrocytes, a middle zone (MZ) with randomly 
distributed spherical chondrocytes, and a deep zone (DZ) with chondrocytes in columnar 
orientation, as observed by haematoxylin-eosin (HE) staining (Figure 4.8a).  By von Kossa 
staining, we could confirm that these cartilage explants do not exhibit a detectable mineral 
content deposition (Figure 4.8b). Both cartilage explants treated with Ca + P or only Ca 
show deposition of mineral content in the ECM but with different deposition patterns. 
Cartilage explants treated with Ca + P exhibit hypertrophic chondrocytes and chondrocyte 
clusters essentially in the deep zone (DZ), as well as initial superficial fibrillation of ECM 
throughout the tissue limits in the three anatomical zones, as observed by haematoxylin-
eosin (HE) staining (Figure 4.8c). Mineral deposition is also observed, by von Kossa 
staining, essentially around of the hypertrophic chondrocytes and chondrocyte clusters of 
the deep zone (DZ) and throughout the tissue limits in the three anatomical zones (Figure 
4.8d). In the cartilage explants treated only with Ca, just by analysis of the von Kossa 
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staining results, is it possible to observe several histological OA features such as a 
reduction in the number of chondrocytes and the presence of hypertrophic chondrocytes in 
the deep zone (DZ), as well as initial superficial fibrillation of ECM throughout the tissue 
limits in the three anatomical zones (Figure 4.8e). In these cartilage explants the mineral 
deposition is present only in the deep zone (DZ), where it is visible high levels of mineral 
deposits in the ECM, but not around the chondrocytes (Figure 4.8e) as observed in the 
cartilage explants treated with Ca + P. Taken together, these results indicate that healthy 
cartilage explants have mineralization capacity in vitro, and despite the two mineralization 
conditions tested induce histological OA features in cartilage explants and mineral 
deposition in its ECM, the condition using Ca only, induces higher levels of mineral 
deposition, corroborating the results obtained by total tissue calcium quantification.  
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Figure 4.8 Mineralization capacity of the in vitro healthy articular cartilage explants assessed by 
histology. Mineralization of in vitro cartilage explants stimulated with a final concentration of 5.4 mM CaCl2 
(Ca) + 2.5 mM KH2PO4 (P) or 5.4 mM CaCl2 (Ca) for 3 weeks. Control (CTR) corresponds to untreated 
cartilage explants. Physiological structures were identified by haematoxylin-eosin (HE) staining a) and c). 
Mineral deposits were detected with silver nitrate by the von Kossa method, and counterstained with 
haematoxylin b), d) and e). SZ correspond to superficial zone, MZ to midlle zone, and DZ to deep zone. 
White arrowhead identifies hypertrophic chondrocyte, black arrow identifies condrocyte clusters, and stars 
indicate mineral deposits. Scare bar represents 100 µm. 
 
4.5   Healthy articular cartilage explants in a co-culture 
system have inflammation capacity  
 
After showing that in vitro healthy articular cartilage explants have inflammation 
and mineralization capacity, as a complementary study for the establishment of a 3D in 
vitro/ex vivo model that simulates OA condition, we have established a co-culture system 
of healthy articular cartilage explants and primary synoviocytes.    
 We started by testing, in this co-culture system, the inflammatory response of 
healthy cartilage explants using two inflammatory condition previously described. One of 
the conditions used was previously described for an explant model of articular cartilage [21] 
(described in section 4.4) and a second condition as described in an inflammatory a canine 
in vitro model of articular cartilage [128]. Thus, 2 mm diameter healthy cartilage disks co-
cultured with primary culture of synoviocytes were stimulated using two different IL-1β 
concentrations (10 ng/ml and 100 ng/ml) for 1 week, and the inflammation of cartilage 
explants was further evaluated by histological analysis. The results show that stimulation 
of the co-culture system with both IL-1β concentrations induce histological OA features on 
the cartilage explants when compared to untreated cartilage explants (CTR). Untreated 
cartilage explants (CTR) show histological features of a healthy cartilage tissue, such as a 
thin superficial zone (SZ) with small and flat chondrocytes, a middle zone (MZ) with 
randomly distributed spherical chondrocytes, and a deep zone (DZ) with chondrocytes in 
columnar orientation, as observed by haematoxylin-eosin (HE) staining (Figure 4.9a), as 
well as a non-significant loss of the content of proteoglycans, as observed by alcian blue 
staining (Figure 4.9b). The cartilage explants stimulated with both IL-1β concentrations 
exhibit histological features typically associated with OA cartilage. In both cartilage 
explants stimulated with IL-1β (Figures 4.9c and 4.9g) and analysed by haematoxylin-
eosin (HE) staining, is observed superficial fibrillation of ECM at the upper (superficial 
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zone (SZ)) limit of tissue, a significant reduction in chondrocytes number in the three 
anatomical zones, as well as hypertrophic chondrocytes and condrocyte clusters in the deep 
zone (DZ) (Figure 4.9e and 4.9h). In cartilage explants stimulated with 10 ng/ml of IL-1β is 
also visible the presence of apoptotic chondrocytes essentially in the superficial zone (SZ) 
and in the middle zone (MZ) (Figure 4.9d). Alcian blue staining shows that 10 ng/ml of IL-
1β induces a proteoglycan content loss in the superficial zone (SZ) and in the middle zone 
(MZ) surface layer of the cartilage explants (Figure 4.9f), while 100 ng/ml of IL-1β 
induced a more significant proteoglycan content loss, affecting the superficial zone (SZ), 
the middle zone (MZ) and the deep zone (DZ) surface layer of the cartilage explants 
(Figure 4.9i). Taken together, these results suggest that, in this co-culture system, IL-1β 
was able to induce an inflammatory response in the cartilage explants, which resulted in 
phenotypic changes of the chondrocytes and ECM degradation.   
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Figure 4.9 Inflammation capacity of the healthy articular cartilage explants in a co-culture system with 
synoviocytes. Inflammation of cartilage explants co-cultured with synoviocytes (HFLS primary cell line) and 
stimulated with IL-1β (10 ng/ml or 100 ng/ml) for 1 week. Control (CTR) corresponds to untreated cartilage 
explants. Physiological structures were identified by haematoxylin-eosin (HE) staining a), c) and g). 
Glycosaminoglycan content was detected with alcian blue counterstained with neutral red b), f) and i). SZ 
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correspond to superficial zone, MZ to midlle zone, and DZ to deep zone. White arrowhead identifies 
hypertrophic chondrocyte (e) and h)), black arrow identifies condrocyte clusters (e) and h)), and black 
arrowhead identifies apoptotic chondrocytes (d). Scare bar represents 100 µm. 
 
After demonstrating the inflammatory capacity of healthy cartilage explants 
stimulated with IL-1β, in a co-culture system, we further evaluated whether IL-1β also 
induced mineralization in these cartilage explants, since, in OA, the chondrocyte 
hypertrophy induced by inflammation of the articular cartilage contributes to the 
calcification of its ECM. For this, we investigated the presence of mineral deposits in 
cartilage explants stimulated with 10 ng/ml and 100 ng/ml of IL-1β, by von Kossa staining. 
The results showed that, when compared to untreated cartilage explants (CTR) (Figure 
4.10a), both IL-1β concentrations used did not show the presence of detectable levels of 
mineral deposition in the cartilage explants (Figure 4.10b and 4.10c), as evaluated by von 
Kossa staining. 
 
 
 
Figure 4.10 Effect of IL-1β on the mineralization of healthy articular cartilage explants in a co-culture 
system with synoviocytes. Mineralization of cartilage explants co-cultured with synoviocytes (HFLS 
primary cell line) and stimulated with IL-1β (10 ng/ml or 100 ng/ml) for 1 week. Control (CTR) corresponds 
to untreated cartilage explants. The presence of mineral deposits was analysed by the von Kossa method, and 
counterstained with haematoxylin a), b) and c). SZ correspond to superficial zone, MZ to midlle zone, and 
DZ to deep zone. Scare bar represents 100 µm. 
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4.6   Marine compound Amentadione does not show a reduce 
the histological OA features in IL-1β-stimulated co-culture 
system in the conditions tested 
 
Since both IL-1β concentrations tested were able to induce an inflammatory 
response in the healthy cartilage explants in a co-culture system of healthy articular 
cartilage and synoviocytes (Figure 4.9), and given that the 100 ng/ml IL-1β concentration 
induced an overly pronounced ECM degradation, degrading a large part of the cartilage 
tissue ECM, and 10 ng/ml IL-1β concentration also showed to be effective in ECM 
degradation, we decided to use the 10 ng/ml IL-1β concentration in further studies using 
this co-culture system. Using the co-culture system, we tested the anti-inflammatory 
potential of Amentadione (YP) in the healthy articular cartilage explants. For this, 2 mm 
diameter healthy cartilage disks co-cultured with primary culture of synoviocytes were 
simultaneously treated with the same YP concentration we used in the chondrocyte and 
synoviocyte articular cell system (10 µM) and stimulated with IL-1β for 1 week. 
Histological changes were analysed by haematoxylin-eosin staining and alcian blue 
staining. The results showed that in cartilage explants treated with 10 µM YP and 
stimulated with 10 ng/ml IL-1β there was no reduction of the histological OA features, 
when compared to the control cartilage explants stimulated with IL-1β (10 ng/ml). The 
cartilage explants stimulated with IL-1β (Figure 4.11a) show, by haematoxylin-eosin (HE) 
staining, superficial fibrillation of ECM at the upper (superficial zone (SZ)) limit of tissue, 
a significant reduction in chondrocytes number in the three anatomical zones compared to 
untreated explants of cartilage (CTR) (results shown in section 4.5), apoptotic 
chondrocytes essentially in the superficial zone (SZ) and in the middle zone (MZ) (Figure 
4.11b), and hypertrophic chondrocytes and chondrocyte clusters in deep zone (DZ) (Figure 
4.11c). In these cartilage explants analysed by alcian blue staining, is observed 
proteoglycan content loss in the superficial zone (SZ) and in the middle zone (MZ) surface 
layer of the cartilage explants (Figure 4.11d). Cartilage explants treated with 10 µM YP 
and stimulated with 10 ng/ml IL-1β (Figure 4.11e) also showed, by haematoxylin-eosin 
(HE) staining, a superficial fibrillation of ECM at the upper (superficial zone (SZ)) limit of 
tissue, a significant reduction in chondrocytes number in the three anatomical zones when 
compared to untreated explants of cartilage (CTR) (results shown in section 4.5). We also 
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could detect the presence of apoptotic chondrocytes essentially in the superficial zone (SZ) 
and in the middle zone (MZ) (Figure 4.11f), and hypertrophic chondrocytes (Figure 4.11g) 
and chondrocyte clusters (Figure 4.11h) in deep zone (DZ). By alcian blue staining, it is 
also observed a proteoglycan content loss in the superficial zone (SZ) and in the middle 
zone (MZ) surface layer of the cartilage explants (Figure 4.11i). Taken together, these 
results show that the concentration of YP tested was not able to reduce the histological OA 
features caused by the inflammation in this healthy cartilage explants co-cultured with 
synoviocytes when using 10 ng/ml IL-1β as stimulation condition. 
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Figure 4.11 Effect of YP on IL-1β-stimulated healthy articular cartilage explants in a co-culture system 
with synoviocytes. Histological analysis of cartilage explants co-cultured with synoviocytes (HFLS primary 
cell line) and stimulated with IL-1β (10 ng/ml) or simultaneously treated with YP (10 µM) and stimulated 
with IL-1β (10 ng/ml) for 1 week. Physiological structures were identified by haematoxylin-eosin (HE) 
staining a) and e). Glycosaminoglycan content was detected with alcian blue counterstained with neutral red 
d) and i). SZ correspond to superficial zone, MZ to midlle zone, and DZ to deep zone. White arrowhead 
identifies hypertrophic chondrocyte (c) and g)), black arrow identifies condrocyte clusters (c) and h)), and 
black arrowhead identifies apoptotic chondrocytes (b) and f)). Scare bar represents 100 µm. 
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V. Discussion 
 
OA is a chronic and disabling disease currently without cure and without approved 
therapies capable of modifying its course [4, 56]. OA treatment is limited to the use of 
therapeutic strategies with modest efficacy that only manage the disease and, in some 
cases, even cause undesirable side effects [4]. There is a clinical need to identify new, 
effective, and safe compounds for the prevention and treatment of this disease. Natural 
products (secondary metabolites) could represent a prolific source of therapeutic agents for 
human diseases [82]. For the OA, some natural compounds tested in pre-clinical research 
and clinical trials have proven effective in the symptomatic treatment and in the disease-
modification, and are describe to cause less side effects. Marine natural products possess 
unique structures and a high level of halogenation, which makes them distinct from their 
terrestrial counterparts and promising compounds for the treatment of several pathological 
conditions including inflammation [80]. In recent years, the anti-inflammatory activity of a 
growing number of marine natural products have been described [80]. Recently, de los 
Reyes et al. showed that several meroditerpenoids isolated from the brown algae 
Cystoseira usneoides significantly inhibited the production of TNF-α in in vitro 
macrophages [120], which suggests its potential as anti-inflammatory and its application as a 
novel therapeutic agents for OA. In this thesis, we have selected three of these 
meroditerpenoids (amentadione (YP), cystodione G (Cyd G) and 11-hydroxyamentadione 
(Cyd K)) and, in order to investigate its potential as therapeutic agent for OA treatment, we 
evaluated its anti-inflammatory potential using in vitro inflammation models, such as a 
LPS and HAP-stimulated THP-1 macrophages culture, a IL-1β-stimulated human articular 
primary cells system and a IL-1β-stimulated co-culture model of ex vivo healthy articular 
cartilage explants and primary synoviocytes. 
The cytotoxic effect evaluation of the selected meroditerpenoids is fundamental to 
determine the safety of these compounds in biological systems. In this study, we tested the 
cytotoxic effect of the marine compounds on the three cell types used in our experiments 
(human THP-1 macrophages, chondrocytes and synoviocytes). De los Reyes et al. had 
previously shown that compounds YP, Cyd G and Cyd K tested at concentrations in the 
range 5−10 μM do not affect human THP-1 macrophages cell viability [120]. Since in 
human chondrocytes and synoviocytes, the cytotoxicity of these compounds was not 
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previously evaluated, we tested the cytotoxic effect of the compounds Cyd G and Cyd K, 
in the range 2.5−10 μM, and showed that this concentrations range are not cytotoxic to the 
three cell types. The non-cytotoxic effect of the third compound (YP) in THP-1 
macrophages, chondrocytes and synoviocytes, in the concentration range 2.5−10 μM, was 
previously shown in our laboratory (unpublished results). Altogether our data demonstrate 
that all the meroditerpenoids compounds concentrations tested are safe for the three cell 
types, allowing its further use in study models using these cells.   
An excellent model for anti-inflammatory activity screening of compounds is the 
monolayer culture of LPS-stimulated macrophages [129]. Macrophages are key players in 
the innate immune response and a major source of secreted mediators, such as pro-
inflammatory cytokines [130]. LPS is an endotoxin with a key role in inducing immune 
response in normal mammalian cells, and is widely used to up-regulate of pro-
inflammatory cytokines in macrophages [130 - 132]. Levels of inflammatory mediators in 
LPS-stimulated macrophages supernatants are reliable markers of inflammation [129]. For 
these reasons, we used this study model to screening the anti-inflammatory activity of the 
selected marine compounds by measuring the production of the pro-inflammatory cytokine 
TNF-α. As previously described in other studies [130, 131], our results showed that LPS-
stimulated activation of macrophages resulted in the significantly increased production of 
pro-inflammatory cytokine TNF-α, confirming the ability of LPS to induce an 
inflammatory response in THP-1 macrophages, and the effectiveness of this model for the 
anti-inflammatory activity screening of compounds. Dexamethasone (Dex) is a known 
anti-inflammatory agent which inhibits the pro-inflammatory cytokines production in LPS-
stimulated macrophages [120]. In this study, we used it as a control anti-inflammatory agent 
of our experiment. We have shown that, like Dex, the three marine compounds (YP, Cyd G 
and Cyd K) significantly inhibited LPS-stimulated production of TNF-α in these cells, 
which corroborates the previous results obtained by de los Reyes et al. [120], and indicates 
that YP, Cyd K and Cyd G have anti-inflammatory activity in LPS-stimulated in vitro 
human macrophages. We have also shown that YP, Cyd G and Cyd K induced a greater 
inhibition of TNF-α production than Dex, showing that the marine compounds tested have 
a higher anti-inflammatory activity than Dex in LPS-stimulated macrophages. Together, 
these data demonstrate the potential of YP, Cyd G and Cyd K in the anti-inflammatory 
area, and indicate that these marine compounds are potentially more effective in inhibiting 
the inflammatory response of macrophages than the known anti-inflammatory agent Dex. 
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 BCP crystals are commonly deposited in osteoarthritic joints, being found in the 
synovial fluid, synovial membrane and articular cartilage of patients with OA [38, 39, 133, 134]. 
These crystals are associated with inflammatory responses in OA [135]. They induce the 
production of MMPs, prostaglandins and pro-inflammatory cytokines by chondrocytes and 
synoviocytes, which suggests its direct pathogenic role in this disease, by contribution to 
synovial inflammation and cartilage degradation [37, 39, 136, 137].  Given that our ultimate goal 
is to validate these marine compounds as anti-inflammatory drugs for the treatment of OA, 
we wanted to test if compounds also show anti-inflammatory activity against a crystal-
induced inflammatory stimulus. BCP crystals have been shown to induce pro-
inflammatory cytokines production, such as IL-1β and TNF-α, in machophages [138, 139]. 
HAP crystals (the main constituent of BCP crystals) and synthetic HAP nanoparticles has 
previously been described to induce TNF-α production, respectively, by peritoneal 
macrophages and THP-1 cells [139, 140]. HAP particles are also described as inducing the 
release of the pro-inflammatory cytokines TNF-α, IL-6 and IL-18 in human monocytes [141, 
142]. In this study we have confirmed the ability of HAP crystals to induce an inflammatory 
response in THP-1 macrophages, by measuring the production of the pro-inflammatory 
cytokine TNF-α. The two HAP crystals concentrations (250 µg/ml and 500 µg/ml) tested, 
in addition to not being cytotoxic in THP-1 macrophages, significantly increased TNF-α 
production in this cell type. We also showed that levels of TNF-α production in THP-1 
human macrophages stimulated with 250 µg/ml HAP concentration are similar to those 
induced by LPS, indicating that this HAP concentration is as effective as LPS in the 
induction of inflammation in these cells. These data suggest that, HAP crystals can also be 
an effective inflammatory agent in THP-1 human macrophages, and monolayer culture of 
HAP-stimulated macrophages can also be used as model for anti-inflammatory activity 
screening of compounds in crystal-induced inflammatory conditions. Thus, demonstrated 
the ability of HAP crystals to induce inflammatory response in THP-1 macrophages, we 
used the monolayer culture of HAP-stimulated macrophages to the anti-inflammatory 
activity screening of the selected marine compounds in inflammatory conditions induced 
by crystals. We showed, for the first time, that the three marine compounds (YP, Cyd G 
and Cyd K) significantly inhibited HAP-stimulated production of TNF-α in these cells, 
which indicates that YP, Cyd K and Cyd G also have anti-inflammatory activity in HAP-
stimulated in vitro human macrophages. Cyd K was the compound that showed a greater 
reduction of TNF-α production, indicating that, of the three marine compounds tested, this 
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is the one with the highest anti-inflammatory activity in human macrophages stimulated 
with HAP crystals. Together, these data confirm the potential of YP, Cyd G and Cyd K in 
the anti-inflammatory area, and suggest them as potential anti-inflammatory drugs 
candidates in inflammatory conditions induced by calcium-containing crystals, such as 
observed in OA.           
 In these assay, we also used the Dex as a control anti-inflammatory agent of our 
experiment, and observed that, in HAP-stimulated macrophages, Dex shows opposite 
results to those observed in LPS-stimulated macrophages, inducing the TNF-α production 
by these cells. There are no studies describing the effect of Dex in inflammation induced 
by HAP crystals or others calcium-containing crystals. Our findings suggest a pro-
inflammatory effect of Dex on in vitro human macrophages stimulated with HAP crystals, 
an effect never reported in the literature. Assay repetition is needed to confirm or refute 
this result. 
Demonstrated the potential of the three selected marine compounds in the anti-
inflammatory area, we decided to select the compound YP in order to investigate its anti-
inflammatory potential in the OA treatment. The role of inflammation in the OA 
development and progression is currently well documented [2, 46]. Thus, pro-inflammatory 
cytokines make ideal candidates for the induction of OA-like biological changes in 
articular cells in vitro, and OA models using these cytokines as induction method are very 
widely used [58]. IL-1β is described to induce inflammation in in vitro synoviocytes and, 
especially, chondrocytes [116 - 118, 126, 143 - 145]. Confirmed the non-cytotoxic effect of YP in 
human chondrocytes and synoviocytes, we used an IL-1β-stimulated in vitro human 
articular primary cells system (cultures of chondrocytes and synoviocytes) to evaluate the 
YP anti-inflammatory potential by analysis of the OA-related inflammation markers gene 
expression.           
 The enzyme cyclo-oxygenase-2 (COX-2) is a potent mediator in inflammation. 
This enzyme is upregulated in inflamed joint tissues by induction of pro-inflammatory 
mediators such as IL-1β, TNFα, and IL-6, and is responsible for production of lipid 
mediators including prostaglandins, such as PGE2, in the OA joint [42]. PGE2 is a principal 
inflammatory mediator in OA, and contributes to the articular cartilage ECM degradation 
[42]. In our in vitro human articular primary cells system, IL-1β inflammatory induction was 
able to activate the inflammatory response by the upregulation of COX-2 expression, in 
both cell systems, although with different gene expression profiles. However, both in 
67 
 
 
chondrocytes and in synoviocytes, the peak COX-2-mediated inflammatory response 
seems to occur at 6 hours after IL-1β stimulation. We showed that YP was able to inhibit 
inflammatory response mediated by increased COX-2 expression levels, in both in vitro 
human chondrocytes and synoviocytes. In chondrocytes, this YP inhibitory effect occurred 
only in the first hours (3 and 6 hours) after IL-1β stimulation, indicating that, in this cell 
system, YP inhibitory effect on the COX-2-mediated inflammatory response is restricted to 
the first few hours after the inflammation induction. Previous studies performed by our 
research group testing the anti-inflammatory potential of YP, by measuring the PGE2 
production, in the same in vitro human articular primary cells system corroborate our 
results. It was found that IL-1β stimulation increases the PGE2 production by human 
chondrocytes and synoviocytes, and that PGE2 production is inhibited by YP (unpublished 
results), which is consistent with our COX-2 expression levels data. Taken together, these 
data show, for the first time, the YP anti-inflammatory activity in an in vitro human 
articular primary cells system, suggesting its therapeutic potential in OA disease. 
 Is currently well documented that, in OA, IL-1β signaling positively regulates 
genes encoding inflammatory molecules such as cytokines (IL-1β, TNF-α, IL-6), 
chemokines (IL-8), COX-2, PGE2 and MMPs in joint cells (chondrocytes and 
synoviocytes), by the NF-kB pathway activation [146]. In this study, we evaluated the NF-
kB activation in the articular primary cells system treated with YP, to explore the possible 
anti-inflammatory action mechanism of this compound in OA disease. In synoviocytes, we 
could not evaluate if YP anti-inflammatory activity occurs by the NF-kB pathway 
activation, because we were not able to measure the expression levels of this transcription 
factor due to constrains on the amount of RNA available. In chondrocytes, we found an 
increase of the NF-kB expression levels induced by IL-1β throughout the tested time-
course, although with peak gene expression observed at 6 hours after IL-1β stimulation. 
These results demonstrate that IL-1β inflammatory induction activate the inflammatory 
response in in vitro human chondrocytes, at least in part, by the NF-kB pathway activation. 
We have also found that the induction of NF-kB expression levels by IL-1β, in 
chondrocytes, was inhibited by YP throughout the tested time-course, demonstrating that 
the anti-inflammatory effect of YP occurs by the NF-kB pathway inhibition. However, we 
have shown in this study that, at 11 hours after the IL-1β stimulation, YP has no inhibitory 
effect on the COX-2-mediated inflammatory response. In chondrocytes, in addition to NF-
kB pathway, inflammatory stimuli also activate the mitogen-activated protein kinase 
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(MAPK) pathway that positively regulates genes encoding inflammatory molecules such as 
COX-2 [147]. Our findings lead us to speculate that in the first hours (3 and 6 hours) after 
IL-1β stimulation the COX-2 expression occurs by the NF-kB pathway activation, but at 
11 hours post-stimulation the COX-2 expression occurs probably by MAPK pathway, 
justifying the inability of YP to inhibit the expression of this inflammatory mediator at this 
time point.  
In addition to the anti-inflammatory potential evaluation of the selected marine 
compounds, in this thesis we started to develop a 3D in vitro/ex vivo OA-model that 
recreates the human articular system and enables a closer-to-in vivo study of human OA 
disease. Although monolayer cultured cells and animal models are often used to study OA-
related features, they have some limitations in providing insight into pathogenic 
mechanisms and in drug validation for human use [31, 61]. In vitro models, such as co-
culture, tissue explant culture and 3D-culture are systems closer to the human system that 
can provide more physiologically relevant information. Our 3D in vitro/ex vivo OA-model 
will be used to study the OA condition through the study of disease-related features, and 
for the test and validation of new drugs for OA, including YP and the other marine 
compounds with anti-inflammatory activity selected after testing in the in vitro articular 
primary cells system. Ex vivo healthy articular cartilage explants will be part of our 3D 
OA-model. Therefore, we started by characterizing an in vitro/ex vivo healthy articular 
cartilage explants system in both inflammatory and mineralization OA conditions.  
 Pro-inflammatory cytokines make ideal candidates for the induction of OA-like 
biological changes in ex vivo tissue explant [58]. IL-1β has been described to induce 
inflammatory OA conditions in various cartilage explant model, including models using 
normal articular cartilage explants from horses, rats and dogs, and human OA cartilage [21, 
128, 148, 149]. In this study, we used IL-1β to stimulate in vitro/ex vivo healthy articular 
cartilage explants and evaluated its ability to induce inflammatory OA conditions in this 
system, by analysis of the OA-related markers gene expression. We evaluated the gene 
expression of an inflammatory mediator (COX-2), a ECM-degrading enzyme (MMP-13) 
and a transcription factor involved in the inflammation OA signalling (NF-kB). Despite our 
results are not statistically significant, since the experiment was performed only once, they 
showed that IL-1β inflammatory induction was able to activate an OA inflammatory and 
catabolic response, respectively, by the upregulation of COX-2 and MMP-13 expression 
levels in in vitro/ex vivo healthy articular cartilage explants for at least 72 hours post-
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stimulation, and suggest that the inflammatory and catabolic response peak induced by IL-
1β in this system occurs at 24 hours post-stimulation. The IL-1β inflammatory induction 
was also able to upregulate NF-kB expression levels essentially 48 hours post-stimulation, 
indicating that, in the time-course by us tested, the activation of NF-kB occurs at 48 hours 
after the IL-1β inflammatory induction. In our experiment using an in vitro human 
chondrocyte system, we showed a peak NF-kB gene expression occurring 6 hours after IL-
1β stimulation, followed by decreased gene expression in the later hours. We also proposed 
that, at 11 hours after IL-1β stimulation, the COX-2 expression in chondrocytes no longer 
occurs by NF-kB pathway. Our present findings, showing residual NF-kB gene expression 
and high COX-2 and MMP-13 gene expression at 24 hours after IL-1β stimulation in in 
vitro/ex vivo healthy articular cartilage explants, support this hypothesis and suggest that 
the peak COX-2 and MMP-13 gene expression observed at 24 hours post-stimulation is 
induced by activation of other intracellular signalling pathway involved in the 
inflammatory response. MAPK and NF-kB pathways are concomitantly activated by IL-1β 
and TNF-α, and are central pathways in OA pathogenesis [150]. Previous reports show the 
role of MAPK pathway in the COX-2 and MMP-13 induction activated by IL-1β, in 
chondrocytes [151, 152]. Although the present experiment needs to be repeated to confirm our 
results, based on our present findings, we speculate that, in chondrocytes, the IL-1β-
induced NF-kB pathway does not remain active throughout the entire inflammatory 
stimulus period, having an initial activation after IL-1β induction and a subsequent 
activation at 48 hours post-stimulus, and that at 24 hours after IL-1β induction is the 
MAPK pathway which positively regulates COX-2 and MMP-13 genes. Therefore, taken 
together, our results indicate that our IL-1β-stimulated in vitro/ex vivo healthy articular 
cartilage explants system is able to recreate the inflammatory conditions observed in OA, 
and suggest that, although both signalling pathways are activated by the IL-1β stimulus, in 
our system could be the MAPK pathway that contributes substantially to the inflammatory 
conditions induction.         
 Mineralization of articular cartilage is a OA feature, which occurs by the calcium-
containing crystals deposition in the ECM of articular cartilage [37]. Previous studies have 
shown that monolayer articular cultures and ex vivo tissue explant stimulated with calcium 
(Ca) and phosphate (P) are able to mineralize [6, 127]. In this study, we have stimulated the 
in vitro/ex vivo healthy articular cartilage explants with two mineralizing conditions (Ca + 
P or Ca) and evaluated its ability to induce mineralization OA conditions in this system, by 
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mineral deposition determination and histological OA features analysis. We found that Ca 
+ P stimulation induces histological OA features, including chondrocytes phenotypic 
changes, such as hypertrophic chondrocytes and chondrocyte clusters, and initial ECM 
articular cartilage degradation, in in vitro/ex vivo healthy articular cartilage explants. 
Although, in vivo, the articular cartilage degradation begins by the ECM fibrillation at the 
superficial zone, in our in vitro/ex vivo healthy articular cartilage explants we observe 
initial ECM degradation induced by Ca + P stimulus throughout the tissue limits in the 
three anatomical zones. Our result might be explained by the fact that, in our in vitro 
system, the outer limits of our full-depth articular cartilage disks are all equally exposed to 
the mineralizing condition. In Ca + P-stimulated in vitro/ex vivo healthy articular cartilage 
explants, we also found increased calcium levels and mineral deposition associated with 
OA histological features observed. Chondrocyte hypertrophy is a key factor in the articular 
cartilage mineralization that occurs in OA disease, and also contribute to the degradation of 
their ECM [33, 38]. The articular cartilage mineralization is often found close to hypertrophic 
chondrocytes and tends to increase as the destruction of cartilage progresses [38]. Our 
findings indicate that hypertrophic chondrocytes and degraded articular cartilage ECM 
induced by Ca + P stimulus contributed to the in vitro/ex vivo healthy articular cartilage 
explants mineralization, giving a mineral deposition pattern similar to observed in OA 
cartilage, which shows that Ca + P stimulation is able to recreate the pattern of articular 
cartilage mineralization observed in human OA. In Ca-stimulated in vitro/ex vivo healthy 
articular cartilage explants, although the tissue sections stained with haematoxylin-eosin 
staining were damaged, we have been able to observe, in tissue sections stained with von 
Kossa staining, histological OA features such as a reduced number of chondrocytes on the 
tissue and hypertrophic chondrocytes. Also in in vitro/ex vivo healthy articular cartilage 
explants stimulated with Ca alone, we observe initial ECM articular cartilage degradation 
throughout the tissue limits in the three anatomical zones, and again we propose that the 
explanation for this could be the equal exposure of all outer limits of full-depth articular 
cartilage disks to the mineralizing condition. In in vitro/ex vivo healthy articular cartilage 
explants stimulated only with Ca, we found an increase of the calcium levels more 
pronounced than using the Ca + P mineralizing condition, as well as a greater mineral 
deposition but without association with histological OA features observed. These findings 
show that the Ca stimulation is able of inducing a stronger ECM mineralization in our in 
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vitro/ex vivo healthy articular cartilage explants than Ca + P stimulation, and also recreate 
the pattern of articular cartilage mineralization observed in human OA.  
In addition to the ex vivo healthy articular cartilage explants, primary synoviocytes 
will also be part of our 3D in vitro/ex vivo OA-model. Co-culture models allow the 
exchange of factors and molecules between cell populations [1]. These systems are 
fundamental for the study of interactions between cell populations in vitro, and provide a 
more representative system of the human system [63]. We have established a co-culture 
model of ex vivo healthy articular cartilage explants and primary synoviocytes using a 
transwell system, and evaluated the ability of two IL-1β concentrations to induce 
inflammatory OA conditions in the co-culture system, by histological OA features 
analysis. We observed that both IL-1β concentrations induce similar histological OA 
features in in vitro/ex vivo healthy articular cartilage explants co-cultured with primary 
synoviocytes. In both IL-1β-stimulated co-culture systems, we found in vitro/ex vivo 
healthy articular cartilage explants displaying chondrocytes phenotypic changes, such as 
hypertrophic chondrocytes and chondrocyte clusters, reduced chondrocytes number on the 
tissue, and initial ECM degradation in the superficial zone of the articular cartilage. In OA, 
joint inflammation is associated with structural changes progression in the articular 
cartilage [49]. We found that both IL-1β concentrations induce proteoglycan content loss in 
our in vitro/ex vivo healthy articular cartilage explants, although this loss is more extensive 
when the 100 ng/ml IL-1β stimulus is used. Using the 100 ng/ml IL-1β stimulus, a large 
part of the proteoglycan content of articular cartilage explants is lost. Taken together, the 
results show that, the two IL-1β concentrations tested are able to induce inflammatory OA 
conditions in our in vitro/ex vivo healthy articular cartilage explants, in a co-culture 
system, by induction of histological OA features and loss of proteoglycan content. 
However, our data indicate that, since the 100 ng/ml IL-1β concentration induce an overly 
ECM degradation of the articular cartilage explants, the 10 ng/ml IL-1β concentration is 
the most appropriate to recreate the inflammatory conditions observed in OA in our co-
culture system.          
 It is known that chondrocyte hypertrophy and proteoglycan content loss contribute 
to the articular cartilage ECM mineralization in OA [37, 38]. Since the IL-1β stimulation 
induced both events in our in vitro/ex vivo healthy articular cartilage explants co-cultured 
with primary synoviocytes, we evaluated whether IL-1β stimulus also contribute to 
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mineralization in our system, but we did not found detectable levels of mineral deposits in 
in vitro/ex vivo healthy articular cartilage explants stimulated with both IL-1β 
concentrations, showing that, in our co-culture system, IL-1β was not able to contribute to 
mineralization of the in vitro/ex vivo healthy articular cartilage explants. A possible 
explanation for the inability of IL-1β contribute to mineralization of the in vitro/ex vivo 
healthy articular cartilage explants is the time of inflammatory stimulus used in our co-
culture system. Probably, a week of IL-1β stimulus is not enough to contribute to the 
articular cartilage ECM mineralization. Further studies, testing this and other longer IL-1β 
stimulation times, in our co-culture system, is needed to explore this hypothesis. 
Shown the YP anti-inflammatory activity in in vitro human articular cells, we used 
our OA inflammation co-culture system to test YP anti-inflammatory activity in a system 
which recreates more closely the human articular system. In this study, we used the same 
YP concentration used in in vitro human articular cells systems (10 µM), and we observed 
that YP was not able to reduce the histological OA features induced by IL-1β stimulus in 
our co-culture system. Although our findings show that, in the conditions tested, YP is not 
able to reduce the histological OA features in in vitro/ex vivo healthy articular cartilage 
explants co-cultured with synoviocytes, further studies, testing other experimental 
conditions, such as different YP concentrations or treatment times, in our co-culture 
system, should be carried out to evaluate the YP anti-inflammatory potential in this in vitro 
system. 
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    VI. Concluding remarks and future perspectives 
 
In this thesis, we have demonstrated the anti-inflammatory activity of the 
meroditerpenoids amentadione (YP), cystodione G (Cyd G) and 11-hydroxyamentadione 
(Cyd K) against inflammatory conditions, including induced by calcium crystals. However, 
in an establish in vitro OA model (in vitro human articular primary cells system), we have 
only shown the anti-inflammatory activity of the meroditerpenoid YP in cytokine-induced 
inflammatory conditions. In the future, it will be relevant to explore the anti-inflammatory 
activity of the meroditerpenoid YP in calcium crystals-induced inflammatory conditions in 
in vitro human articular primary cells system. Within the duration of this project we were 
unable to obtain results about the YP mechanism of action in primary synoviocytes system 
and the possible role in the NF-kB pathway and this should be evaluated in the future, to 
explore the anti-inflammatory action mechanism of YP in these cells. Although, in this 
work, we have begun to develop a 3D in vitro/ex vivo OA-model, several parameters are 
currently being studied and optimized for application in future experiments. In a co-culture 
system of healthy articular cartilage explants and primary synoviocytes, the experimental 
conditions we used did not allow us to observed mineralization of the ECM articular 
cartilage usually associated with OA cartilage. Future work testing other experimental 
conditions, namely longer pro-inflammatory cytokines stimulation times, is needed to 
explore the ability to induce mineralization OA conditions in our in vitro OA system. In 
this work using this co-culture system, YP did not show anti-inflammatory activity, so we 
plan to repeat the experiment using a higher number of samples, different YP 
concentrations and treatment times in order to investigate the YP therapeutic potential in a 
system closer to the human articular system. In addition, we are also interested in pursuing 
with the testing on the therapeutic potential of the compounds Cyd G and Cyd K shown to 
have anti-inflammatory effect using the THP-1 cell culture in vitro assay, by testing their 
effect in the articular primary cells system and select the most promising compound for 
further testing in the OA co-culture system. 
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Appendices 
 
Appendice I - Total RNA extraction protocol of biological samples 
(adapted from Chomczynski and Sacchi [69]) 
 
1. Using liquid nitrogen, crush cartilage explants collected from the culture plate until 
are reduced to powder, and add 1 ml solution D per 100 mg tissue; or add 1 ml 
solution D per 1 × 107 cells directly to the culture dish or flask for cells grown in 
monolayer, scrape the culture surface with a scraper to lyse the cells, and resuspend 
the lysate at least ten times with a sterile, disposable 1-ml pipette tip, for fragment 
the DNA. 
2. Transfer tissue or cell lysates to a polypropylene tube.  
3. Pass the lysate, sequentially, by syringe with filters of the 18G×2’’, 20G×1’’ and 
23G×1’’. 
4. Add to 1 ml of lysate, 0.1 ml of 2 M sodium acetate, pH 4.0, and mix thoroughly by 
inversion. 
5. Add to 1 ml of lysate, 1 ml of water-saturated phenol and mix thoroughly by 
inversion. 
6. Add to 1 ml of lysate, 0.2 ml of chloroform/isoamyl alcohol (49:1) and shake 
vigorously by hand for 10 seconds. 
7. Cool the samples on ice for 15 minutes. 
8. Centrifuge at 10,000g for 15 minutes, at 4°C. 
9. Transfer very carefully, using a pipette, the upper aqueous phase, which contains 
mostly RNA, to a clean tube. Discard the lower organic phase. 
10. Add to the aqueous phase 1 ml isopropanol to precipitate the RNA, and mix by 
inversion. 
11. Incubate the samples for at least 1hour (can be overnight), at -20°C. 
12. Centrifuge at 10,000g for 30 minutes, at 4°C.  
13. Discard the supernatant. Dissolve the RNA pellet in 0.5 ml solution D and vortex 
for a few seconds. 
14. Transfer to a 1.5-ml microcentrifuge tube. 
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15. Add 0.5 ml isopropanol and mix by inversion. 
16. Incubate the samples for at least 3hours (can be overnight), at -20°C. 
17. Centrifuge at 10,000g for 30 minutes, at 4°C. 
18. Discard the supernatant. Resuspend the RNA pellet with 0.5 ml of 80% ethanol and 
vortex for a few seconds. 
19. Centrifuge at 10,000g for 15 minutes, at 4°C. 
20.  Discard the supernatant. Air-dry the RNA pellet, at room temperature. 
21. Dissolve the RNA pellet in RNase-free water (40 µl of water per 80 µg RNA 
pellet), at 4°C. 
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